

Full Schedule

184 results found

Wednesday, April 22, 2026

5:00 PM - 8:00 PM PT
ASAM Registration Open
Location: Palm Foyer, Level 2

9:00 PM - 10:00 PM PT
Mutual Help (Open Meeting)
Location: Bankers Hill, Level 3

Thursday, April 23, 2026

7:00 AM - 8:00 AM PT
Mutual Help (Open Meeting)
Location: Bankers Hill, Level 3

7:30 AM - 7:00 PM PT
ASAM Registration Open
Location: Palm Foyer, Level 2

8:00 AM - 9:00 AM PT
Pre-Conference Course Continental Breakfast
Location: Harbor Foyer, Level 2

9:00 AM - 4:30 PM PT
Benzodiazepine Tapering Decisions: Basic Principles through Complex Management Pre-Conference Course
Separate Registration Required



9:00 AM - 9:40 AM PT
Setting the Stage
Location: Harbor A-F, Level 2

Presenter: Emily Brunner, MD – Hazelden Betty Ford Foundation

Pre-Conference Course

9:40 AM - 10:30 AM PT
Overcoming Patient Resistance
Location: Harbor A-F, Level 2

Presenter: Chinyere Ogonna, MD, MPH – Kaiser Permanente San Jose

Pre-Conference Course

10:30 AM - 10:45 AM PT

Refreshment Break

Location: Harbor A-F, Level 2

Pre-Conference Course

10:45 AM - 11:35 AM PT

Tapering 101: Minimizing Withdrawal

Location: Harbor A-F, Level 2

Presenter: Emily Brunner, MD – Hazelden Betty Ford Foundation

Pre-Conference Course

11:35 AM - 12:20 PM PT

Tapering Guidance: Case-based Discussions

Location: Harbor A-F, Level 2

Presenter: Chinyere Ogonna, MD, MPH – Kaiser Permanente San Jose

Pre-Conference Course

12:20 PM - 12:30 PM PT

Q&A session

Location: Harbor A-F, Level 2

Presenter: Emily Brunner, MD – Hazelden Betty Ford Foundation

Presenter: Chinyere Ogonna, MD, MPH – Kaiser Permanente San Jose

Pre-Conference Course

12:30 PM - 1:30 PM PT

Lunch Break

Location: Harbor A-F, Level 2

Pre-Conference Course

1:30 PM - 2:10 PM PT

Psychiatric Comorbidities

Location: Harbor A-F, Level 2

Presenter: Donovan Maust

Pre-Conference Course

2:10 PM - 3:00 PM PT

Co-occurring Substance Use Disorders

Location: Harbor A-F, Level 2

Presenter: Stephen Holt, MD, MS, FACP, FASAM – Yale School of Medicine

Pre-Conference Course

2:50 PM - 3:00 PM PT

Q&A session

Location: Harbor A-F, Level 2

Presenter: Donovan Maust

Presenter: Stephen Holt, MD, MS, FACP, FASAM – Yale School of Medicine

Pre-Conference Course

3:00 PM - 3:15 PM PT

Refreshment Break

Location: Harbor A-F, Level 2

Pre-Conference Course

3:15 PM - 3:55 PM PT

Patients with Unique Clinical Needs

Location: Harbor A-F, Level 2

Presenter: Donovan Maust

Presenter: Stephen Holt, MD, MS, FACP, FASAM – Yale School of Medicine

Pre-Conference Course

3:55 PM - 4:15 PM PT

Panel Discussion

Location: Harbor A-F, Level 2

Presenter: Emily Brunner, MD – Hazelden Betty Ford Foundation

Presenter: Stephen Holt, MD, MS, FACP, FASAM – Yale School of Medicine

Presenter: Donovan Maust

Presenter: Chinyere Ogonna, MD, MPH – Kaiser Permanente San Jose

Pre-Conference Course

4:15 PM - 4:30 PM PT

Wrap-Up & Closing Remarks

Location: Harbor A-F, Level 2

Presenter: Stephen Holt, MD, MS, FACP, FASAM – Yale School of Medicine

Presenter: Emily Brunner, MD – Hazelden Betty Ford Foundation

Pre-Conference Course

9:00 AM - 4:30 PM PT

Improving Care for Women with Substance Use Disorders: From Evidence to Action Pre-Conference Course



Separate Registration Required

9:00 AM - 9:30 AM PT

Welcome & Course Overview

Location: Harbor G-I, Level 2

Presenter: Katrina Mark, MD, FACOG, FASAM – University of Maryland Medical Center

Presenter: Hendree E. Jones, PhD, LP – University of North Carolina at Chapel Hill

Pre-Conference Course

9:30 AM - 10:30 AM PT

Session 1: Trauma-Responsive Care

Location: Harbor G-I, Level 2

Presenter: Hendree E. Jones, PhD, LP – University of North Carolina at Chapel Hill

Pre-Conference Course

10:30 AM - 10:45 AM PT

Refreshment Break

Location: Harbor G-I, Level 2

Pre-Conference Course

10:45 AM - 11:30 AM PT

Session 2: Pregnancy & Breastfeeding

Location: Harbor G-I, Level 2

Presenter: Katrina Mark, MD, FACOG, FASAM – University of Maryland Medical Center

Pre-Conference Course

11:30 AM - 12:15 PM PT

Session 3: Co-occurring Psychiatric Conditions

Location: Harbor G-I, Level 2

Presenter: Smita Das, MD, PhD, MPH – Stanford University

Pre-Conference Course

12:15 PM - 12:30 PM PT

Patient Voice & Reflection

Location: Harbor G-I, Level 2

Pre-Conference Course

12:30 PM - 1:30 PM PT

Lunch Break

Location: Harbor G-I, Level 2

Pre-Conference Course

1:30 PM - 2:15 PM PT

Session 4: Adolescents & Addiction

Location: Harbor G-I, Level 2

Presenter: J. Deanna Wilson, MD, MPH – University of Pennsylvania

Pre-Conference Course

2:15 PM - 3:00 PM PT

Session 5: Older Women & Addiction

Location: Harbor G-I, Level 2

Presenter: Benjamin H. Han, MD – University of California San Diego

Pre-Conference Course

3:00 PM - 3:15 PM PT

Refreshment Break

Location: Harbor G-I, Level 2

Pre-Conference Course

3:15 PM - 4:00 PM PT

Session 6: Policy Considerations

Location: Harbor G-I, Level 2

Presenter: Hendree E. Jones, PhD, LP – University of North Carolina at Chapel Hill

Non-presenting author: Cara A. Poland, MD, MEd, DFASAM – Michigan State University

Pre-Conference Course

4:00 PM - 4:15 PM PT

Patient Voice & Reflection

Location: Harbor G-I, Level 2

Pre-Conference Course

4:15 PM - 4:30 PM PT

Wrap-Up & Closing Remarks

Location: Harbor G-I, Level 2

Presenter: Hendree E. Jones, PhD, LP – University of North Carolina at Chapel Hill

Presenter: Katrina Mark, MD, FACOG, FASAM – University of Maryland Medical Center

Presenter: Benjamin H. Han, MD – University of California San Diego

Presenter: Smita Das, MD, PhD, MPH – Stanford University

Presenter: J. Deanna Wilson, MD, MPH – University of Pennsylvania

Non-presenting author: Cara A. Poland, MD, MEd, DFASAM – Michigan State University

Pre-Conference Course

4:00 PM - 7:00 PM PT

ASAM Booth Open

Location: Palm Foyer, Level 2

5:00 PM - 7:00 PM PT

Exhibit Hall Open

Location: Grand Hall, Level 1

5:00 PM - 7:00 PM PT

West Coast Welcome Reception

Location: Grand Hall, Level 1

6:00 PM - 6:30 PM PT

First-Time Attendee Meet-Up

Location: Lounge 1-3, Grand Hall, Level 1

6:00 PM - 7:00 PM PT

Region I Meeting (NY)

Location: Solana Beach, Level 3

6:00 PM - 7:00 PM PT

Region IX Meeting (Canada/International)

Location: Old Town, Level 2

6:00 PM - 7:00 PM PT

Region VII Meeting (AR, OK, KS, LA, MO, NE, TX)

Location: La Jolla, Level 2

6:30 PM - 8:00 PM PT

President's Donor Reception (Invitation Only)

Location: Bayview, Seaport Tower Level 32

7:00 PM - 8:00 PM PT

Concurrent Sessions #1



7:30 PM - 8:30 PM PT

New Member Dessert Reception (Invitation Only)

Location: Coronado Foyer, Level 4

9:00 PM - 10:00 PM PT

Mutual Help (Open Meeting)

Location: Bankers Hill, Level 3

Friday, April 24, 2026

7:00 AM - 8:00 AM PT

Mutual Help (Open Meeting)

Location: Bankers Hill, Level 3

7:00 AM - 8:00 AM PT

Outdoor Yoga Class

Location: Marina Courtyard, Level 1

7:00 AM - 8:00 AM PT

Scholarship Networking Breakfast Meeting

Location: Hillcrest, Level 3

7:30 AM - 8:30 AM PT

Continental Breakfast

Location: Grand Hall, Level 1

7:30 AM - 3:15 PM PT

Exhibit Hall Open

Location: Grand Hall, Level 1

7:30 AM - 4:00 PM PT

ASAM Registration Open

Location: Palm Foyer, Level 2

7:30 AM - 6:00 PM PT

ASAM Booth Open

Location: Palm Foyer, Level 2

7:45 AM - 8:15 AM PT

Forensic Addiction Medicine SIG Meet-Up

Location: Lounge 1, Grand Hall, Level 1

7:45 AM - 8:15 AM PT

Meet JAM & ASAM Weekly Editors

Location: Lounge 2, Grand Hall, Level 1

7:45 AM - 8:15 AM PT

Primary Care & Family Medicine SIG Meet-Up

Location: Lounge 3, Grand Hall, Level 1

8:30 AM - 9:45 AM PT**Opening General Session – Resilience & Navigating Uncertainty**

Location: Seaport Ballroom, Level 2

Presenter: Michael Ungar, PhD – Dalhousie University

Moderator: Stephen M. Taylor, MD, MPH, DFAPA, DFASAM – Pathway Healthcare Services, LLC

General Session**9:30 AM - 5:00 PM PT****Donor & Ruth Fox Alumni Lounge**

Location: Seaport Foyer, Level 2

9:45 AM - 10:45 AM PT**Adolescent Criteria Reception (Invitation Only)**

Location: Hillcrest, Level 3

9:45 AM - 10:45 AM PT**Break**

Location: Grand Hall, Level 1

9:45 AM - 10:45 AM PT**Scientific Poster Session 1a**

Location: Harbor Foyer, Level 2

10:00 AM - 10:30 AM PT**Addiction Consult SIG Meet-Up**

Location: Lounge 1, Grand Hall, Level 1

10:00 AM - 10:30 AM PT**Harm Reduction SIG Meet-Up**

Location: Lounge 2, Grand Hall, Level 1

10:00 AM - 10:30 AM PT**Nicotine & Tobacco SIG Meet-Up**

Location: Lounge 3, Grand Hall, Level 1

10:00 AM - 10:30 AM PT**Twelve Step SIG Meet-Up**

Location: Bankers Hill, Level 3

10:45 AM - 12:00 PM PT**Concurrent Sessions #2****10:45 AM - 12:00 PM PT****Artificial Intelligence and the Future of Addiction Medicine**

Location: Seaport Ballroom, Level 2

Presenter: Sara J. Polley, MD, FAPA, FASAM – Vantage Mental Health

Presenter: Emily Brunner, MD – Hazelden Betty Ford Foundation

Presenter: Michael Eiden, PhD, LCSW, LCADC, CSAT, CCS – Eiden Integrative Counseling

Presenter: Daniel Kaufmann, PhD, LPC, LMHC – Kindbridge Behavioral Health | Grand Canyon University

Focus Session



10:45 AM - 12:00 PM PT

Effectiveness of Extended-Release Buprenorphine in OUD: Results from NIDA CTN Studies

Developed in Collaboration with the National Institute of Drug Abuse

Location: Gaslamp, Level 2

Presenter: Geetha A. Subramaniam, MD, DLFAPA, DFAACAP – NIDA

Presenter: Michelle Lofwall, MD, MS, DFAPA, DFASAM – University of KY College of Medicine, Center on Drug and Alcohol Research

Presenter: Gail D'Onofrio, MD, MS, FACEM, FASAM – Yale School of Medicine

Collaborative Session



10:45 AM - 12:00 PM PT

Helping Patient Care Make Cent\$: Billing and Coding Strategies for Addiction Medicine

Location: Harbor A-C, Level 2

Presenter: Darve Robinson, MD – Cooper University Hospital

Presenter: Rachel Haroz, MD – Cooper University Health Care

Presenter: Jeffrey Jaeger, MD, FASAM – Cooper University Health Care, Cooper Medical School of Rowan University

Non-presenting author: Susan Holzberg, n/a – Cooper University Hospital

Non-presenting author: Greg Langan, DHSc, LSW, MPH – Cooper University Health Care

Workshop Session



10:45 AM - 12:00 PM PT

Housing is Health: A Health System's Approach to Housing and Community Partnership

Location: Regatta, Level 4

Presenter: Juleigh Nowinski Konchak, MD MPH FASAM – Cook County Health

Presenter: Lydia Karch, MPH – Cook County Health

Presenter: Chante Gamby, LCSW – Cook County Health

Presenter: Vauna Hernandez, NCRS, CPRS – Phoenix Recovery Support Services

Presenter: Cayse M. Powell, MD, MPH – Cook County Health/Northwestern University Feinberg School of Medicine

Non-presenting author: Keiki Hinami, MD MS – Cook County Health

Non-presenting author: Sonia Roxo, BSN, RN – Cook County Health

Focus Session



10:45 AM - 12:00 PM PT

Implementing Hospital and ED SUD Care: Translating ASAM Guidance into Action

Location: Harbor G-I, Level 2

Presenter: Sarah E. Wakeman, MD, FASAM – Mass General Brigham

Presenter: Honora Englander, MD – Oregon Health & Science University

Presenter: Itai Danovitch, MD, MBA, DFAPA, DFASAM – Cedars-Sinai

Workshop Session



10:45 AM - 12:00 PM PT

Improving Methadone Dose Confirmation: Innovative Approaches and Challenges of CFR Part 2

Location: Balboa, Level 2

Presenter: William M. Garneau, MD, MPH, MHS – Johns Hopkins School of Medicine

Presenter: Malik Burnett, MD, MBA, MPH – REACH Health Services

Presenter: Sophia Peng, MD FASAM – Rush University Medical Center

Presenter: Aaron Ferguson, BSW – National Survivors Union - Community Medical Services

Non-presenting author: Maia Gottlieb, MPH – CRISP

Non-presenting author: Nicole M. Gastala, MD, MS – UI Health Mile Square Health Center - University of Illinois Chicago

Non-presenting author: Corrina Klein, B.A. – Johns Hopkins University

Focus Session



10:45 AM - 12:00 PM PT

On the Rocks: Fixing Our Fractured Alcohol Policies

Location: Coronado DE, Level 4

Presenter: Marlene C. Lira, MPH – Johns Hopkins Bloomberg School of Public Health

Presenter: Marissa Esser, PhD, MPH – Esser Public Health Consulting, LLC

Presenter: Mike Marshall – U.S. Alcohol Policy Alliance

Non-presenting author: Cara A. Poland, MD, MEd, DFASAM – Michigan State University

Non-presenting author: Regina LaBelle, JD – Georgetown University

Non-presenting author: Lauren Hendy, PhD – Workit Health

Workshop Session



10:45 AM - 12:00 PM PT

Perinatal Alcohol Use Disorder: Management Considerations Across the Care Continuum

Location: Coronado A-C, Level 4

Presenter: Niraj R. Chavan, MD, MPH, FACOG, FASAM – Saint Louis University / SSM Health

Presenter: Sonja Williams, DO, FACOOG, FASAM – Cullman AL

Presenter: Maria Manriquez, MD, FACOG, FASAM – University of Arizona, College of Medicine - Phoenix

Workshop Session



10:45 AM - 12:00 PM PT

Pharmacologic Innovations in Alpha-2 Agonist Withdrawal Management in EDs and ICUs

Location: Harbor D-F, Level 2

Presenter: Jeanmarie Perrone, MD – Perelman School of Medicine at the University of Pennsylvania

Presenter: Michael J. Lynch, MD FACEP FACMT – UPMC and UPMC Health Plan

Presenter: Joseph D'Orazio, MD, FAAEM, FACMT, FASAM, FCPP – Cooper Medical School of Rowan University

Presenter: Brendan Hart, MD, PhD – Temple University

Presenter: Kory S. London, MD – Thomas Jefferson University

Presenter: Andrew Otte, PhD – Purdue University

Focus Session



10:45 AM - 12:00 PM PT

Unprescribed Influence: Navigating Benzodiazepine Tapering in the Age of Social Media

Location: America's Cup, Level 4

Presenter: Kristina Reinstatler, PharmD, MBA, BCPP – UC Health

Presenter: Daniel Bebo, MD – UC Health

Focus Session



12:00 PM - 1:30 PM PT

Lunch Break

Location: Grand Hall, Level 1

12:15 PM - 1:15 PM PT

Region III Meeting (CT, MA, ME, NH, RI, VT)

Location: Solana Beach, Level 3

12:15 PM - 1:15 PM PT

Region V Meeting (DE, DC, GA, MD, NC, SC, VA, WV)

Location: Old Town, Level 2

12:15 PM - 1:15 PM PT

Region VIII Meeting (AK, AZ, CO, HI, ID, MT, NM, ND, NV, OR, SD, UT, WA, WY)

Location: La Jolla, Level 2

12:15 PM - 1:15 PM PT

Region X Meeting (AL, FL, KY, MS, PR, TN, VI)

Location: Hillcrest, Level 3

12:30 PM - 1:00 PM PT

Integrative Behavioral Health for Addiction Medicine SIG Meet-Up

Location: Lounge 1, Grand Hall, Level 1

12:30 PM - 1:00 PM PT

Pain & Palliative Care SIG Meet-Up

Location: Lounge 2, Grand Hall, Level 1

12:30 PM - 1:00 PM PT

Physicians Health SIG Meet-Up

Location: Lounge 3, Grand Hall, Level 1

12:30 PM - 1:30 PM PT

Scientific Poster Session 1b

Location: Harbor Foyer, Level 2

1:30 PM - 2:45 PM PT

Concurrent Sessions #3



1:30 PM - 2:45 PM PT

Advanced Management of Alcohol Withdrawal: Case-Based, Evidence-Informed Solutions

Location: Seaport Ballroom, Level 2

Presenter: Tessa L. Steel, MD, MPH – University of Washington

Presenter: Melissa B. Weimer, DO, MCR, DFASAM – Yale School of Medicine

Presenter: Ryan JJ Buckley, MD, MPH – Yale School of Medicine

Workshop Session



1:30 PM - 2:45 PM PT

Bridging Barriers: 3 Jail-Based MOUD Models That Save Lives and Restore Hope

Location: Coronado A-C, Level 4

Presenter: Danae N. DiRocco, MD – Creighton University School of Medicine, CHI Health

Presenter: Eric Weintraub, MD – University of Maryland

Presenter: Hendree E. Jones, PhD, LP – University of North Carolina at Chapel Hill

Presenter: Renita J. Bartley, Pharm D, CDCA – MetroHealth Hospital - Correctional Medicine

Workshop Session



1:30 PM - 2:45 PM PT

Collaborative Care for OUD with Co-Occurring Mental Disorders in Safety-Net Primary Care

Location: Coronado DE, Level 4

Presenter: Colleen M. McCullough, MPA – RAND

Presenter: Grace M. Hindmarch, BSPH – RAND and UCLA

Presenter: Alex R. Dopp, PhD – RAND

Presenter: Brian Hurley, MD, M.B.A., FAPA, DFASAM – Los Angeles County Department of Public Health

Non-presenting author: Katherine Watkins, MD, MSHS – RAND Corporation

Focus Session



1:30 PM - 2:45 PM PT

Drug Testing: Practical Interpretation Beyond the Urine Cup

Location: Harbor D-F, Level 2

Presenter: JoAn Laes, MD – Allina

Presenter: Stephanie T. Weiss, MD, PhD, FASAM, FAACT – NIDA/NIH

Presenter: Evan S. Schwarz, MD, FASAM – UCLA

Presenter: Robert Cole Pueringer, MD – Essentia Health

Non-presenting author: Jeremiah D. Fairbanks, DO – Allina

Non-presenting author: Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM – University of Rochester Medical Center

Focus Session



1:30 PM - 2:45 PM PT

Expanding Access to Adolescent Substance Use Disorder Treatment

Location: Gaslamp, Level 2

Presenter: William Coe, MD, MPH – NYU Grossman School of Medicine

Presenter: Jordan P. Davis, PhD – NYU Langone Child Study Center

Presenter: Pantea Farahmand, MD – NYU Langone

Non-presenting author: Katarzyna Liwski, DO – NYU Langone

Focus Session



1:30 PM - 2:45 PM PT

Low-Threshold Injectable PrEP in People Who Use Drugs

Location: Regatta, Level 4

Presenter: Ethan Cowan, MD, MS – RUTGERS THE STATE UNIV OF NEW JERSEY

Presenter: Ruchi M. Fitzgerald, MD, FAAFP FASAM – PCC Community Wellness Center-MacNeal Hospital-Loyola Univ

Presenter: Francesco Tani, DO – Howard Brown Health // PCC Community Wellness

Presenter: Cayse M. Powell, MD, MPH – Cook County Health/Northwestern University Feinberg School of Medicine

Focus Session



1:30 PM - 2:45 PM PT

Opioid Angst in the Pain Clinic: New Multisociety Consensus Guidelines

Location: Harbor A-C, Level 2

Presenter: Gregory D. Rudolf, MD – Swedish Health Services

Presenter: Lynn Kohan, MD – University of Virginia

Presenter: Mark C. Bicket, MD, PhD, FASA – University of Michigan

Focus Session



1:30 PM - 2:45 PM PT

Peer Recovery Coaching to Enhance MOUD Outcomes

Location: Balboa, Level 2

Presenter: Kevin R. Wenzel, PhD – Maryland Treatment Centers/Mountain Manor

Presenter: Marc Fishman, MD, FASAM – Maryland Treatment Centers

Presenter: Katie Lee, CPRS (Certified Peer Recovery Specialist) – Maryland Treatment Centers

Focus Session



1:30 PM - 2:45 PM PT

TMS for Treatment of Addiction and Its Psychiatric Comorbidities: Safety and Efficacy

Location: America's Cup, Level 4

Presenter: Hamed Ekhtiari, MD, PhD, DFISAM – University of Texas Southwestern

Presenter: Kathleen T. Brady, MD, PhD – Medical University of South Carolina

Presenter: Manish K. Jha, MD – UTSW

Presenter: Victor Tang, MD – University of Toronto

Focus Session



1:30 PM - 2:45 PM PT

Unusual Clues: Hidden Presentations of Substance Use Disorders Across Clinical Disciplines

Location: Harbor G-I, Level 2

Presenter: Omar Hassan, MD – Hennepin Healthcare

Presenter: Cailean Dakota MacColl, BA, BS – University of Minnesota Medical School

Presenter: Ese B. Aghenta, MD, MPH, FASAM – North Memorial Hospital

Presenter: Seleipiri Iboroma Akobo, MD, MBA, MPH, FASAM – Maine Medical Center

Non-presenting author: Charles P. Reznikoff, MD, FASAM, FACP – Hennepin Healthcare, University of Minnesota

Non-presenting author: Jacob K. Smith, MD – Oregon Health & Science University

Non-presenting author: Audrey A. Jacobsen, MD, MPH – Hennepin Healthcare

Workshop Session



2:45 PM - 3:15 PM PT

Break

Location: Grand Hall, Level 1

2:45 PM - 3:15 PM PT

LGBTQ+ SIG Meet-Up

Location: Lounge 1, Grand Hall, Level 1

2:45 PM - 3:15 PM PT

Women & Substance Use Disorders SIG Meet-Up

Location: Lounge 3, Grand Hall, Level 1

3:15 PM - 4:30 PM PT

Concurrent Sessions #4



3:15 PM - 4:30 PM PT

Annual Review of Addiction Medicine: Highest Impact Publications 2025-26

Location: Seaport Ballroom, Level 2

Presenter: Sarah E. Wakeman, MD, FASAM – Mass General Brigham

Presenter: Joshua D. Lee, MD – NYULH

Focus Session



3:15 PM - 4:30 PM PT

Clinical Insights on Emerging Misuse of Performance and Image Enhancing Drugs

Location: Harbor D-F, Level 2

Presenter: Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM – University of Rochester Medical Center

Presenter: Jeffrey Brent, MD, PhD, – University of Colorado

Presenter: Stephanie T. Weiss, MD, PhD, FASAM, FAACT – NIDA/NIH

Presenter: Jason Kirby, DO, MBA, FASAM – Landmark Recovery

Presenter: Stephen M. Taylor, MD, MPH, DFAPA, DFASAM – Pathway Healthcare Services, LLC

Workshop Session

3:15 PM - 4:30 PM PT

Considerations for Use of Addiction Medications in Adolescents with SUD

Location: Balboa, Level 2

Presenter: Sara J. Polley, MD, FAPA, FASAM – Vantage Mental Health

Presenter: Sandra Gomez-Luna, MD, FAPA, DFASAM – Yale School of Medicine

Presenter: Lisa R. Fortuna, MD, MPH – University of California Riverside

Focus Session



3:15 PM - 4:30 PM PT

Critical Care Addiction Medicine: Considerations for Buprenorphine in Intubated Patients

Location: Gaslamp, Level 2

Presenter: Anthony Spadaro, MD MPH – University of Pennsylvania

Presenter: Jessica J. Krueger, MD – Rutgers New Jersey Medical School

Presenter: Robert Cole Pueringer, MD – Essentia Health

Presenter: Ryan JJ Buckley, MD, MPH – Yale School of Medicine

Workshop Session



3:15 PM - 4:30 PM PT

How Medicaid Powers Addiction Treatment: Care, Coverage and Consequences

Location: Harbor A-C, Level 2

Presenter: Sherry Nykiel, MD – Delaware Division of Medicaid and Medical Assistance

Presenter: Brian Hurley, MD, M.B.A., FAPA, DFASAM – Los Angeles County Department of Public Health

Workshop Session



3:15 PM - 4:30 PM PT

Long-Acting Injectable Buprenorphine for Birthing and Parenting People with OUD

Location: Harbor G-I, Level 2

Presenter: Davida M. Schiff, MD – Massachusetts General Hospital

Presenter: Marcela C. Smid, MD MA MS – University of Utah Health

Presenter: Melinda Ramage, FNP-BC, CARN-AP, LCAS – Governor's Institute

Presenter: Vania P. Rudolf, MD, MPH, FAAFP, DFASAM – Associate Professor, Department of Family Medicine, University of Washington

Presenter: Tricia E. Wright, MD, MS, FACOG, DFASAM – University of California, San Francisco

Non-presenting author: Sharon Ostfeld-Johns, MD, IBCLC – Yale School of Medicine

Workshop Session



3:15 PM - 4:30 PM PT

Seeking Stability in OUD Care: Person-Centered Transitions from Methadone to Buprenorphine

Location: Coronado A-C, Level 4

Presenter: Ezra Lyon, MD, FASAM – Bridge Community Health Clinic

Presenter: Ian Latham, MD – Gundersen Health System/Emplify Health

Workshop Session



3:15 PM - 4:30 PM PT

Supporting ASAM's Level 1.0 Remission Monitoring through Recovery Management Checkups

Location: America's Cup, Level 4

Presenter: Dennis P. Watson, PhD, MA, MS – Chestnut Health Systems

Presenter: Michael L. Dennis, PhD – Chestnut Health Systems

Presenter: Sarah Messmer, MD – University of Illinois at Chicago

Presenter: R. Corey Waller, MD, MS, FACEP, DFASAM – Shore Capital Partners

Non-presenting author: Navdeep Kang, PsyD – Acadia Healthcare

Non-presenting author: Christine E. Grella, PhD – Chestnut Health Systems

Workshop Session



3:15 PM - 4:30 PM PT

Teaching Tomorrow's Doctors: Incorporating Evidence-Based SUD Training in Medical Schools

Location: Coronado DE, Level 4

Presenter: Rohit Chaparala, MPH – University of Alabama at Birmingham

Presenter: Daryn Papenfuse, MPH – Michigan State University

Presenter: Li Li, MD, PhD – University of Alabama at Birmingham

Non-presenting author: Cara A. Poland, MD, MEd, DFASAM – Michigan State University

Non-presenting author: Madison Walsh, MS – Michigan State University

Workshop Session



3:15 PM - 4:30 PM PT

Updates on HCV Elimination in the US

Developed in Collaboration with American Association for the Study of Liver Diseases

Location: Regatta, Level 4

Presenter: Ponni Perumalswami, MD – AASLD

Presenter: Carolyn Wester, MD, MPH – CDC

Presenter: Pauli Gray – USCF DeLIVER Care

Presenter: Oluwaseun Falade-Nwulia, MBBS, MPH – Johns Hopkins School of Medicine

Collaborative Session



4:30 PM - 4:45 PM PT

Break

Location: Seaport Foyer, Level 2

4:45 PM - 6:00 PM PT**General Session – Understanding the Evolving Drug Landscape: From Epidemiology to Clinical Practice**

Location: Seaport Ballroom, Level 2

Presenter: Traci C. Green, PhD, MSc – Brandeis University, Heller School for Social Policy and Management The Warren Alpert School of Medicine of Brown University Brown University School of Public Health

Presenter: Joseph D'Orazio, MD, FAAEM, FACMT, FASAM, FCPP – Cooper Medical School of Rowan University

Presenter: Kirsten E. Smith, PhD, LMSW – Dial Square LLC

Moderator: Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM – University of Rochester Medical Center

General Session

**6:00 PM - 7:30 PM PT****Surf's Up Social**

Location: Pool Deck, Level 4

9:00 PM - 10:00 PM PT**Mutual Help (Open Meeting)**

Location: Bankers Hill, Level 3

Saturday, April 25, 2026**7:00 AM - 8:00 AM PT****Award Recipient Breakfast (Invitation Only)**

Location: Hillcrest, Level 3

7:00 AM - 8:00 AM PT**Mutual Help (Open Meeting)**

Location: Bankers Hill, Level 3

7:00 AM - 8:00 AM PT**Outdoor Yoga Class**

Location: Marina Courtyard, Level 1

7:00 AM - 8:00 AM PT**Region VI Meeting (IA, IL, IN, MI, MN, WI)**

Location: La Jolla, Level 2

7:30 AM - 8:30 AM PT**Continental Breakfast**

Location: Grand Hall, Level 1

7:30 AM - 1:30 PM PT**Exhibit Hall Open**

Location: Grand Hall, Level 1

7:30 AM - 2:00 PM PT**ASAM Registration Open**

Location: Palm Foyer, Level 2
7:30 AM - 6:00 PM PT ASAM Booth Open Location: Palm Foyer, Level 2
7:45 AM - 8:15 AM PT Associate Members Meet-Up Location: Lounge 1, Grand Hall, Level 1
7:45 AM - 8:15 AM PT Psychedelic Medicine SIG Meet-Up Location: Lounge 3, Grand Hall, Level 1
8:30 AM - 9:45 AM PT Policy & Science General Session – Medicaid Matters: Policy Changes and Implications for Practice Location: Seaport Ballroom, Level 2 Presenter: Yngvild Olsen, MD, MPH, DFASAM – Manatt Health Services Presenter: Regina LaBelle, JD – Georgetown University Presenter: Katie Greene, MPP – National Academy for State Health Policy (NASHP) Moderator: Stephen M. Taylor, MD, MPH, DFAPA, DFASAM – Pathway Healthcare Services, LLC General Session
9:30 AM - 5:00 PM PT Donor & Ruth Fox Alumni Lounge Location: Seaport Foyer, Level 2
9:45 AM - 10:45 AM PT Break Location: Grand Hall, Level 1
9:45 AM - 10:45 AM PT Scientific Poster Session 2a Location: Harbor Foyer, Level 2
10:00 AM - 10:30 AM PT Cannabis & Pregnancy SIG Meet-Up Location: Lounge 1, Grand Hall, Level 1
10:00 AM - 10:30 AM PT Child & Adolescent Addictions SIG Meet-Up Location: Lounge 2, Grand Hall, Level 1
10:00 AM - 10:30 AM PT Criminal Justice SIG Meet-Up Location: Lounge 3, Grand Hall, Level 1
10:45 AM - 12:00 PM PT

Concurrent Sessions #5



10:45 AM - 12:00 PM PT

Addiction Medicine and the Law: Navigating Common Problems in Practice

Location: Harbor G-I, Level 2

Presenter: Michael F. Weaver, MD, DFASAM – University of Texas Health Science Center at Houston

Presenter: Kelly J. Clark, MD, MBA, DFAPA, DFASAM – Addiction Crisis Solutions

Presenter: Margaret Jarvis, MD, DFASAM – Geisinger Health System

Workshop Session



10:45 AM - 12:00 PM PT

Bridging the Gap between Science and Clinical Practice

Developed in Collaboration with the National Institutes of Health and the Food and Drug Administration

Location: Regatta, Level 4

Presenter: Wilson M. Compton, MD, MPE – National Institute on Drug Abuse

Presenter: Geetha A. Subramaniam, MD, DLFAPA, DFAACAP – NIDA

Presenter: George F. Koob, PhD – NIAAA

Presenter: Marta Sokolowska, PhD – Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration

Presenter: Ken I. Freedman, MD, MS, MBA, DFASAM, FACP, AGAF – Aetna / CVS Health

Presenter: Tami L. Mark, PhD – RTI International

Collaborative Session



10:45 AM - 12:00 PM PT

Enhancing Access with Direct to Inject Buprenorphine: Evidence and Implementation

Location: Harbor D-F, Level 2

Presenter: Josh Luftig, PA-C – The Bridge Center at The Public Health Institute

Presenter: Arianna D. Campbell, DMSc, MPH, PA-C, CAQ-EM, DFAAPA – The Bridge Center at The Public Health Institute

Presenter: Andrew A. Herring, MD – Alameda Health System

Focus Session



10:45 AM - 12:00 PM PT

Expanding Telehealth to Optimize Buprenorphine Access and Mitigate Rural Treatment Barriers

Location: Coronado DE, Level 4

Presenter: Jeanmarie Perrone, MD – Perelman School of Medicine at the University of Pennsylvania

Presenter: Michael J. Lynch, MD FACEP FACMT – UPMC and UPMC Health Plan

Presenter: Nicole M. Gastala, MD, MS – UI Health Mile Square Health Center - University of Illinois Chicago

Non-presenting author: Nicole O'Donnell, BA. CRS – University of Pennsylvania

Non-presenting author: Eric Weintraub, MD – University of Maryland

Non-presenting author: Margaret Lowenstein, MD – University of Pennsylvania

Non-presenting author: Gilly Gehri, MBE – University of Pennsylvania

Workshop Session



10:45 AM - 12:00 PM PT

Finding Connection: Addressing Loneliness in People Living with Substance Use Disorder

Location: Coronado A-C, Level 4

Presenter: Devin Oller, MD – UCSF Division of General Internal Medicine

Presenter: Irina (Era) V. Kryzhanovskaya, MD – UCSF

Presenter: Sienna Kurland, MD, MPH – UCSF

Non-presenting author: Jessica Ristau, MD – UCSF

Workshop Session



10:45 AM - 12:00 PM PT

High Risk at Every Stage: Cannabis Exposure During Critical Periods of Development

Location: Gaslamp, Level 2

Presenter: Sukhmeet Sandhu, MD – Children's Hospital Colorado / University of Colorado School of Medicine

Presenter: Danae Massengill, MD – Children's Hospital Colorado, University of Colorado School of Medicine

Presenter: Laurie S. Halmo, MD, FAAP – University of Colorado School of Medicine

Focus Session



10:45 AM - 12:00 PM PT

Improving Engagement and Retention in Opioid Treatment through Measurement-Based Care

Location: Balboa, Level 2

Presenter: Renee M. Cloutier, PhD – HEALing Measures Center; Center for Research on Health Care

Presenter: Robert Ryan, LPC, NCC, PMP – University of Pittsburgh

Non-presenting author: Ani Lessley, BA – Northwestern University Feinberg School of Medicine

Non-presenting author: Kelli Scott, PhD – Northwestern University Feinberg School of Medicine

Focus Session



10:45 AM - 12:00 PM PT

Promoting Integrated Care Throughout the SUD and Mental Health Treatment Systems

Location: Harbor A-C, Level 2

Presenter: R. Corey Waller, MD, MS, FACEP, DFASAM – Shore Capital Partners

Presenter: Lisa R. Fortuna, MD, MPH – University of California Riverside

Presenter: Anish Dhamija, MD – Imperial Beach Community Clinic

Presenter: Brian Hurley, MD, M.B.A., FAPA, DFASAM – Los Angeles County Department of Public Health

Focus Session



10:45 AM - 12:00 PM PT

The Right Dose, Every Day

Location: America's Cup, Level 4

Presenter: Ruth A. Potee, MD DFASAM – Behavioral Health Network

Presenter: Ari Kriegsmann, MD FASAM – Behavioral Health Network

Presenter: Daniel Liauw, MD MPH FASAM – Massachusetts General Hospital/Harvard Medical School

Focus Session



10:45 AM - 12:00 PM PT

When AUD Isn't the Only Diagnosis: Navigating Co-Occurring Psychiatric Conditions

Location: Seaport Ballroom, Level 2

Presenter: Smita Das, MD, PhD, MPH – Stanford University

Presenter: Stephanie A. Vail, PharmD, MPH, BCPP, FCCP, FAAPP – University of New England

Focus Session



12:00 PM - 1:30 PM PT

Lunch Break

Location: Grand Hall, Level 1

12:15 PM - 1:15 PM PT

Region II Meeting (CA)

Location: La Jolla, Level 2

12:15 PM - 1:15 PM PT

Region IV Meeting (NJ, OH, PA)

Location: Hillcrest, Level 3

12:30 PM - 1:00 PM PT

International Addiction Medicine SIG SIG Meet-Up

Location: Lounge 1, Grand Hall, Level 1

12:30 PM - 1:00 PM PT

Medical Toxicology SIG Meet-Up

Location: Lounge 2, Grand Hall, Level 1

12:30 PM - 1:00 PM PT

Science Initiative SIG Meet-Up

Location: Lounge 3, Grand Hall, Level 1

12:30 PM - 1:30 PM PT

Scientific Poster Session 2b

Location: Harbor Foyer, Level 2

1:30 PM - 2:45 PM PT

Concurrent Sessions #6



1:30 PM - 2:45 PM PT

Beyond Screening: Implementing a Response to Substance Use Coercion in Clinical Practice

Location: Gaslamp, Level 2

Presenter: Ilana Hull, MD, MSc – University of Pittsburgh School of Medicine

Presenter: Diana Samberg, MD, MS – University of Pittsburgh School of Medicine

Presenter: Carole Warshaw, MD – National Center on Domestic Violence, Trauma, and Mental Health

Non-presenting author: Heather Phillips, MA – National Center on Domestic Violence, Trauma, and Mental Health

Non-presenting author: Lauren T. Narbey, CNM, PhD – Duquesne University

Focus Session



1:30 PM - 2:45 PM PT

Bridging Gaps: Clinical and Ethical Challenges for Patients with Addiction and Cancer

Location: America's Cup, Level 4

Presenter: Janet J. Ho, MD MPH – University of California, San Francisco

Presenter: Katrina S. Nickels, MD, DFASAM – University of Kentucky College of Medicine

Presenter: A. Justine Landi, MD, MPH – University of Louisville

Presenter: Julie W. Childers, MD, FASAM – University of Pittsburgh

Workshop Session



1:30 PM - 2:45 PM PT

Envisioning a Continuum of Care for Behavioral Addictions

Location: Harbor D-F, Level 2

Presenter: Sara J. Polley, MD, FAPA, FASAM – Vantage Mental Health

Presenter: Michael Eiden, PhD, LCSW, LCADC, CSAT, CCS – Eiden Integrative Counseling

Presenter: Daniel Kaufmann, PhD, LPC, LMHC – Kindbridge Behavioral Health | Grand Canyon University

Presenter: Margaret Jarvis, MD, DFASAM – Geisinger Health System

Non-presenting author: Emily Brunner, MD – Hazelden Betty Ford Foundation

Focus Session



1:30 PM - 2:45 PM PT

Expanding Your "Us": Strengthening Police & SUD Provider Partnerships to Build RESILIENCE

Location: Coronado DE, Level 4

Presenter: Jennifer L. Holm, MSW, MA-TASL, LMSW, BEI I – Traverse City Police Department

Presenter: Paula Lipinski, MSW, – Addiction Treatment Services

Workshop Session



1:30 PM - 2:45 PM PT

Incorporating Artificial Intelligence into your Research Workflow: A Hands-On Workshop

Location: Coronado A-C, Level 4

Presenter: Cara Borelli, DO – Yale School of Medicine

Presenter: Alyssa Cheng, DO – Yale University

Presenter: Molly MacInnes Perri, MD – University of Illinois College of Medicine Rockford

Presenter: Lilian Denzler – Yale, UCL

Workshop Session



1:30 PM - 2:45 PM PT

The Short-Term Impacts of Drug Decriminalization in British Columbia

Location: Balboa, Level 2

Presenter: Cayley Russell, MA – Centre for Addiction and Mental Health

Presenter: Sameer Imtiaz, PhD – Center for Addiction and Mental Health

Presenter: Juls Budau, MSW – UBC School of Population & Public Health

Focus Session



1:30 PM - 2:45 PM PT

Treatment of Alcohol Use Disorder in Patients with Liver Disease

Location: Harbor A-C, Level 2

Presenter: Divya Ayyala-somayajula, MD MAS – Thomas Jefferson University

Presenter: Thomas Bottyan, MD – VA Northern California

Presenter: Steven Tate, MD, MSc, FASAM, FACP – Stanford University School of Medicine

Presenter: Deirdra Kelly, MD – University of California Davis

Non-presenting author: Gargi Bhattacharya, MD – Stanford University School of Medicine

Focus Session



1:30 PM - 2:45 PM PT

TV 101: Mastering Media Skills to Pitch and Promote Addiction Treatment

Location: Harbor G-I, Level 2

Presenter: Lee Radosh, MD, FAAFP, FASAM – Reading Hospital and Tower Health Medical Group

Presenter: Jodi Radosh, PhD – Alvernia University

Focus Session



1:30 PM - 2:45 PM PT

Withdrawal, Discontinuation Syndromes, or Nil for Atypical Substances of Misuse

Location: Seaport Ballroom, Level 2

Presenter: Robert Cole Pueringer, MD – Essentia Health

Presenter: Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM – University of Rochester Medical Center

Presenter: JoAn Laes, MD – Allina

Presenter: Ashley Haynes, MD – University of Kansas, School of Medicine - Wichita

Non-presenting author: Sarah Usher, MD – University of Minnesota

Non-presenting author: Evan S. Schwarz, MD, FASAM – UCLA

Focus Session



2:45 PM - 3:15 PM PT

Ice Cream Social

Location: Seaport Foyer, Level 2

3:15 PM - 4:30 PM PT

ASAM Annual Awards & Updates

Location: Seaport Ballroom, Level 2

4:30 PM - 4:45 PM PT

Break

Location: Seaport Foyer, Level 2

4:45 PM - 6:00 PM PT

Concurrent Sessions #7



4:45 PM - 6:00 PM PT

Beyond Withdrawal: Optimizing Pain in the Opioid Tolerant Patient

Location: Harbor D-F, Level 2

Presenter: Joseph D'Orazio, MD, FAAEM, FACMT, FASAM, FCPP – Cooper Medical School of Rowan University

Presenter: Christine Collins, MD – Cooper University Hospital

Non-presenting author: Sam J. Stern, MD – Temple University Hospital

Focus Session



4:45 PM - 6:00 PM PT

Ensuring Access to Medications for Opioid Use Disorder During Climate Disasters

Location: America's Cup, Level 4

Presenter: Matthew Salzman, MD, MPH – Cooper Medical School of Rowan University

Presenter: Cordelia Stearns, MD, AAHIVS – High Country Community Health

Presenter: Rachel Haroz, MD – Cooper University Health Care

Non-presenting author: Elizabeth Cerceo, MD, DCM – Cooper Medical School of Rowan University

Workshop Session



4:45 PM - 6:00 PM PT

Hot Takes: Smoking Practices and Emerging Risks Amid Stimulants, Fentanyl, and Torches

Location: Harbor G-I, Level 2

Presenter: Honora Englander, MD – Oregon Health & Science University

Presenter: Elizabeth M. Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM – University of Wisconsin, Madison School of Medicine and Public Health

Presenter: James Duffy – Smoke Works

Presenter: William H. Eger, PhD(c), MPH – UC San Diego

Presenter: Alexander Y. Walley, MD, MSc, DFASAM – Boston University Chobanian & Avedisian School of Medicine

Presenter: Michael Incze, MD, MEd – University of Utah

Presenter: Kayla Houston, BS – Father Joe's Villages

Workshop Session



4:45 PM - 6:00 PM PT

Innovations in Addiction Medicine on the Street: SUD treatments for the Unhoused

Location: Balboa, Level 2

Presenter: Katia Cnop, DO – USC Street Medicine / Keck School of Medicine

Presenter: Camilo Zaks, MD, FAAFP – USC Street Medicine/ Keck School of Medicine of USC

Presenter: Shane Collins, MD, MS – University of Southern California

Focus Session



4:45 PM - 6:00 PM PT

Innovations in Polysubstance Overdose Response: More Effective and Compassionate Response

Location: Coronado DE, Level 4

Presenter: Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM – Kelly S. Ramsey Consulting, LLC

Presenter: Kailin Louise See – Homeless Healthcare Los Angeles

Presenter: Mary Brewster, MSW – Ad Astra Harm Reduction

Workshop Session



4:45 PM - 6:00 PM PT

Let's Practice: Vaping Cessation Strategies for Youth

Location: Harbor A-C, Level 2

Presenter: Trish Tulloch, MD MS FRCPC – University of Toronto

Presenter: Amit YOSEF Rotem, MD – Centre for Addiction and Mental Health (CAMH)

Presenter: Naima Javaid, MD – Centre for Addiction and Mental Health

Workshop Session



4:45 PM - 6:00 PM PT

Medication Call Backs in MOUD: Balancing Diversion Control and Patient-Centered Care

Location: Regatta, Level 4

Presenter: Robert C. Sherrick, MD, DFASAM – Community Medical Services

Presenter: Hillary Tamar, MD, FASAM – Community Medical Services

Presenter: Aaron Ferguson, BSW – National Survivors Union - Community Medical Services

Focus Session



4:45 PM - 6:00 PM PT

Phenobarbital Protocols on Trial: A Point-Counterpoint Debate

Location: Seaport Ballroom, Level 2

Presenter: Robert Cole Pueringer, MD – Essentia Health

Presenter: Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM – University of Rochester Medical Center

Presenter: JoAn Laes, MD – Allina

Presenter: Evan S. Schwarz, MD, FASAM – UCLA

Non-presenting author: Lewis S. Nelson, MD, MBA – Florida Atlantic University College Of Medicine

Non-presenting author: Jeremiah D. Fairbanks, DO – Allina

Non-presenting author: Katie Krieger, MD – University of Minnesota

Focus Session



4:45 PM - 6:00 PM PT

The Healthcare Professional's Core Resource on Alcohol: Improving Alcohol-Related Care

Developed in Collaboration with the National Institute on Alcohol Abuse and Alcoholism

Location: Gaslamp, Level 2

Presenter: Laura E. Kwako, PhD – NIAAA

Presenter: George F. Koob, PhD – NIAAA

Collaborative Session



4:45 PM - 6:00 PM PT

Injectable Medications for Addiction: Hands-On Practice for Providers

Room Capacity Limited to 175

Location: Coronado A-C, Level 4

Presenter: Megan Ehret, PharmD, MS, BCPP, FAAPP – University of Maryland, School of Pharmacy

Presenter: Hannah Wilkoff, PharmD, BCPP – University of Maryland School of Pharmacy

Presenter: Vincent S. Cavaliere, PharmD, MM, BCPP – Spring Grove Hospital Center - University of Maryland School of Pharmacy

Presenter: Jacob E. McGregor, PharmD – University of Maryland School of Pharmacy

Presenter: Rebekah Torchon, PharmD, MS – University of Maryland Eastern Shore

Presenter: Adrian Quezada Gonzalez, PharmD – University of Maryland Medical Center

Workshop Session



9:00 PM - 10:00 PM PT

Mutual Help (Open Meeting)

Location: Bankers Hill, Level 3

Sunday, April 26, 2026

7:00 AM - 8:00 AM PT

Mutual Help (Open Meeting)

Location: Bankers Hill, Level 3

7:00 AM - 8:00 AM PT

Scholarship Networking Breakfast Meeting

Location: Hillcrest, Level 3

7:30 AM - 8:30 AM PT

Continental Breakfast

Location: Harbor Foyer, Level 2

7:30 AM - 10:00 AM PT

ASAM Registration Open

Location: Palm Foyer, Level 2

7:30 AM - 11:30 AM PT

ASAM Booth Open

Location: Palm Foyer, Level 2

8:30 AM - 9:45 AM PT

Concurrent Sessions #8



8:30 AM - 9:45 AM PT

Addressing Substance Use Disorders in Transplant Candidates and Recipients

Location: Gaslamp, Level 2

Presenter: Thomas Bottyan, MD – VA Northern California

Presenter: Divya Ayyala-somayajula, MD MAS – Thomas Jefferson University

Presenter: Steven Tate, MD, MSc, FASAM, FACP – Stanford University School of Medicine

Presenter: Gargi Bhattacharya, MD – Stanford University School of Medicine

Non-presenting author: Deirdra Kelly, MD – University of California Davis

Workshop Session



8:30 AM - 9:45 AM PT

Benzodiazepine Tales from the Office - Defining Success and Sharing Stories

Location: Harbor A-C, Level 2

Presenter: Anthony J. Accurso, MD, FASAM, AAHIVS – Bergen New Bridge Medical Center

Presenter: Sonya Del Tredici, MD – WellSpan Health

Workshop Session



8:30 AM - 9:45 AM PT

Beyond Kratom: Novel Products Containing 7-OH, Pseudo, MGM, and Kava

Location: Harbor D-F, Level 2

Presenter: Katherine Hill, MPH – Yale School of Public Health

Presenter: Kirsten E. Smith, PhD, LMSW – Dial Square LLC

Presenter: Edward W. Boyer, MD PhD – The Ohio State University

Focus Session



8:30 AM - 9:45 AM PT

Blueprints for an Inpatient Addiction Consult Service at Pediatric Institutions

Location: Balboa, Level 2

Presenter: Sukhmeet Sandhu, MD – Children's Hospital Colorado / University of Colorado School of Medicine

Presenter: Deepa R. Camenga, MD, MHS, FAAP – Yale School of Medicine

Presenter: Margot Zarin-Pass, MD – Children's Minnesota

Presenter: Abby Montague, MD – Children's Minnesota

Focus Session



8:30 AM - 9:45 AM PT

Building Community Advisory Boards to Strengthen Patient Voice in Addiction Treatment

Location: America's Cup, Level 4

Presenter: Elizabeth M. Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM – University of Wisconsin, Madison School of Medicine and Public Health

Presenter: Renee M. Cloutier, PhD – HEALing Measures Center; Center for Research on Health Care

Presenter: Michael Incze, MD, MEd – University of Utah

Presenter: Evan Done – Utah Support Advocates for Recovery Awareness

Workshop Session



8:30 AM - 9:45 AM PT

Innovative Strategies for Medication Initiation in Opioid Use Disorder

Location: Harbor G-I, Level 2

Presenter: Pouya Azar, MD, FRCPC, DABAM – Vancouver General Hospital & The University of British Columbia

Presenter: Andrew A. Herring, MD – Alameda Health System

Presenter: Melissa B. Weimer, DO, MCR, DFASAM – Yale School of Medicine

Presenter: Laura G. Kehoe, MD, MPH – Harvard Medical School, MGH Bridge Clinic, Baymark/HCRC OTP

Workshop Session



9:45 AM - 10:15 AM PT

Break

Location: Harbor Foyer, Level 2

10:15 AM - 11:30 AM PT

Concurrent Sessions #9



10:15 AM - 11:30 AM PT

Behavior Change Tools for Prescribers Treating Alcohol Use Disorder

Developed in Collaboration with the Providers Clinical Support System - Medications for Alcohol Use Disorder

Location: Harbor G-I, Level 2

Presenter: Carla B. Marienfeld, MD, DFAPA, DFASAM – University of California San Diego

Presenter: John O'Neil, LCSW, LADC – Yale Addiction Medicine Consult Service

Presenter: Eve N. Lasswell, PsyD – University of California San Diego

Collaborative Session



10:15 AM - 11:30 AM PT

Cracking the Code: Building a Statewide Perinatal SUD Network

Location: Harbor A-C, Level 2

Presenter: Melinda Ramage, FNP-BC, CARN-AP, LCAS – Governor's Institute

Presenter: Hendree E. Jones, PhD, LP – University of North Carolina at Chapel Hill

Presenter: Olivia A. Caron, PharmD, BCACP, CPP – MAHEC

Non-presenting author: Mateo Eckstat, MD, MPH – REACH Program, Cone Health

Non-presenting author: Nicole F. Ross, LCAS, CCS, NCPSS – BHG Recovery

Non-presenting author: Elisabeth Johnson, PhD, FNP-BC, CARN-AP, LCAS – UNC Chapel Hill

Non-presenting author: Michael Baca-Atlas, MD, FASAM – UNC

Non-presenting author: David Hallmark Ryan, MD, FASAM, FACOG – ECU Health

Workshop Session



10:15 AM - 11:30 AM PT

Expanding Access: Low-Barrier, Hepatitis C Treatment in Addiction Clinics

Location: America's Cup, Level 4

Presenter: Marissa Tan, DO, MPH, MAS – Cooper

Presenter: Xin Gao, PharmD, MSc – Cooper University Healthcare

Presenter: Rachel Ehrman-Dupre, MD – Cooper University Healthcare

Workshop Session



10:15 AM - 11:30 AM PT

Gas Station Highs

Location: Harbor D-F, Level 2

Presenter: Alaina R. Steck, MD, FACMT, FASAM – Emory University

Presenter: Steven Quam, MD – University of Minnesota

Presenter: JoAn Laes, MD – Allina

Presenter: Jeremiah D. Fairbanks, DO – Allina

Non-presenting author: Robert Cole Pueringer, MD – Essentia Health

Non-presenting author: Evan S. Schwarz, MD, FASAM – UCLA

Non-presenting author: Lewis S. Nelson, MD, MBA – Florida Atlantic University College Of Medicine

Focus Session



10:15 AM - 11:30 AM PT

LAI Buprenorphine in Criminal Justice Settings: Strategies and Tools for Implementation

Location: Gaslamp, Level 2

Presenter: Eowyn Rieke, MD MPH – Multnomah County Department of Health/Corrections Health

Presenter: Stephen Kane, MD MPH – Multnomah County Health Department

Presenter: Kendra Birnley, RN, MA, MEd, PhDc – Multnomah County Health Dept, Corrections Health

Non-presenting author: Ederlinda Ortiz, CHW – Multnomah County Health Dept/Corrections Health

Non-presenting author: David Green – Multnomah County Transition Services Program

Non-presenting author: Courtney M. Kenney – Multnomah County Health Department

Focus Session



10:15 AM - 11:30 AM PT

Retention Beyond Benchmarks: Patient-Centered Tele-MOUD Care in the Fentanyl Era

Location: Balboa, Level 2

Presenter: Laura Monico, PhD – Boulder Care

Presenter: Ayesha Appa, MD – Boulder Care & UCSF

Presenter: Danielle Bellosi, NCPRSS, CPRC – Boulder Care

Presenter: Elizabeth Bambury, MPH – Boulder Care

Non-presenting author: Jennifer K. Foreman, DNP, AGNP-C, WHNP-BC – Boulder Care

Non-presenting author: Melody Avila, DNP – Boulder Care

Non-presenting author: Stephen A. Martin, MD, EdM – Boulder Care

Focus Session



Benzodiazepine Tapering Decisions: Basic Principles through Complex Management Pre-Conference Course

Setting the Stage

Thursday, April 23, 2026

9:00 AM - 9:40 AM PT

Location: Harbor A-F, Level 2

Presenter(s)

[Emily Brunner, MD](#)

Supervising physician consultant
Hazelden Betty Ford Foundation
Lake Elmo, Minnesota

Disclosure(s):

Emily Brunner, MD: No financial relationships to disclose

Overcoming Patient Resistance

Thursday, April 23, 2026

9:40 AM - 10:30 AM PT

Location: Harbor A-F, Level 2

Presenter(s)

[Chinyere Ogbonna, MD, MPH](#)

Medical Director, Addiction Medicine & Recovery Services
Kaiser Permanente San Jose
San Jose, California

Tapering 101: Minimizing Withdrawal

Thursday, April 23, 2026

10:45 AM - 11:35 AM PT

Location: Harbor A-F, Level 2

Presenter(s)

[Emily Brunner, MD](#)

Supervising physician consultant
Hazelden Betty Ford Foundation
Lake Elmo, Minnesota

Disclosure(s):

Emily Brunner, MD: No financial relationships to disclose

Tapering Guidance: Case-based Discussions

Thursday, April 23, 2026

11:35 AM - 12:20 PM PT

Location: Harbor A-F, Level 2

Presenter(s)

[Chinyere Ogbonna, MD, MPH](#)

Medical Director, Addiction Medicine & Recovery Services
Kaiser Permanente San Jose
San Jose, California

Psychiatric Comorbidities

Thursday, April 23, 2026

1:30 PM - 2:10 PM PT

Location: Harbor A-F, Level 2

Presenter(s)

[Donovan Maust](#)

Co-occurring Substance Use Disorders

Thursday, April 23, 2026

2:10 PM - 3:00 PM PT

Location: Harbor A-F, Level 2

Presenter(s)

[Stephen Holt, MD, MS, FACP, FASAM](#)

Associate Professor of Medicine
Yale School of Medicine
New Haven, Connecticut

Patients with Unique Clinical Needs

Thursday, April 23, 2026

3:15 PM - 3:55 PM PT

Location: Harbor A-F, Level 2

Presenter(s)

[Donovan Maust](#)

[Stephen Holt, MD, MS, FACP, FASAM](#)

Associate Professor of Medicine
Yale School of Medicine
New Haven, Connecticut

Improving Care for Women with Substance Use Disorders: From Evidence to Action Pre-Conference Course

Session 1: Trauma-Responsive Care

Thursday, April 23, 2026

9:30 AM - 10:30 AM PT

Location: Harbor G-I, Level 2

Presenter(s)

[Hendree E. Jones, PhD, LP](#)

Professor
University of North Carolina at Chapel Hill
Carrboro, North Carolina

Disclosure(s):

Hendree E. Jones, PhD, LP: No financial relationships to disclose

Session 2: Pregnancy & Breastfeeding

Thursday, April 23, 2026

10:45 AM - 11:30 AM PT

Location: Harbor G-I, Level 2

Presenter(s)

[Katrina Mark, MD, FACOG, FASAM](#)

Associate Professor
University of Maryland Medical Center
Baltimore, Maryland

Disclosure(s):

Katrina Mark, MD, FACOG, FASAM: No financial relationships to disclose

Session 3: Co-occurring Psychiatric Conditions

Thursday, April 23, 2026

11:30 AM - 12:15 PM PT

Location: Harbor G-I, Level 2

Presenter(s)

Smita Das, MD, PhD, MPH

Clinical Associate Professor
Stanford University
Cupertino, California

Disclosure(s):

Smita Das, MD, PhD, MPH: No financial relationships to disclose

Session 4: Adolescents & Addiction

Thursday, April 23, 2026

1:30 PM - 2:15 PM PT

Location: Harbor G-I, Level 2

Presenter(s)

J. Deanna Wilson, MD, MPH

Assistant Professor of Family Medicine and Community Health and Adolescent Medicine
University of Pennsylvania
Avondale, Pennsylvania

Disclosure(s):

J. Deanna Wilson, MD, MPH: No financial relationships to disclose

Session 5: Older Women & Addiction

Thursday, April 23, 2026

2:15 PM - 3:00 PM PT

Location: Harbor G-I, Level 2

Presenter(s)

Benjamin H. Han, MD

Associate Professor
University of California San Diego
San Diego, California

Disclosure(s):

Benjamin H. Han, MD: No financial relationships to disclose

Session 6: Policy Considerations

Thursday, April 23, 2026

3:15 PM - 4:00 PM PT

Location: Harbor G-I, Level 2

Presenter(s)

Hendree E. Jones, PhD, LP

Professor
University of North Carolina at Chapel Hill
Carrboro, North Carolina

Non-presenting author(s)

[Cara A. Poland, MD, MEd, DFASAM](#)

Associate Professor
Michigan State University
Michigan State University
Alto, Michigan

Developing Addiction Medicine Fellowships Developed in Collaboration with the American College of Academic Addiction Medicine

Thursday, April 23, 2026

7:00 PM - 8:00 PM PT

Location: Harbor A-C, Level 2

Presenter(s)

[Timothy K. Brennan, MD, MPH](#)

Chief of Clinical Services in Addiction
Icahn School of Medicine at Mount Sinai
Mount Sinai
New York, New York

[Jeanette M. Tetrault, MD, FACP](#)

Professor of Medicine
Yale School of Medicine
New Haven, Connecticut

[Alexander Y. Walley, MD, MSc, DFASAM](#)

Professor of Medicine
Boston University Chobanian & Avedisian School of Medicine
Boston, Massachusetts

Join us for an engaging presentation on "Developing Addiction Medicine Fellowships," where we'll explore strategies to build robust programs that address the growing demand for addiction medicine specialists. Discover how to cultivate the next generation of physicians equipped to tackle the challenges of substance use disorders with evidence-based care and innovative training approaches.

Learning Objectives:

Learners will be able to:

- Describe the current role of fellowship training programs in meeting Addiction Medicine workforce needs.
- List key activities that fellows engage in during the Addiction Medicine training year.
- Identify the steps required to start an Addiction Medicine fellowship program.

Disclosure(s):

Timothy K. Brennan, MD, MPH: No financial relationships to disclose

Jeanette M. Tetrault, MD: No financial relationships to disclose

Alexander Y. Walley, MD, MSc: No financial relationships to disclose

The Continuing Certification Program in Addiction Medicine Through ABPM

Developed in Collaboration with the American Board of Preventive Medicine

Thursday, April 23, 2026

7:00 PM - 8:00 PM PT

Location: Harbor G-I, Level 2

Presenter(s)

Michael F. Weaver, MD, DFASAM

Professor & Medical Director
University of Texas Health Science Center at Houston
The University of Texas Health Science Center at Houston
Houston, Texas

Christopher J. Ondrula, JD

Chief Executive Officer
American Board of Preventive Medicine
Chicago, Illinois

Mia Katzenberger

Continuing Certification Manager
American Board of Preventive Medicine
Chicago, Illinois

The American Board of Preventive Medicine offers certification in Addiction Medicine and many attendees will have achieved this. Those who are already certified in Addiction Medicine by ABPM need to participate in the ABPM's Continuing Certification Program (CCP). Detailed information will be provided about the transition from MOC to CCP, including requirements for calendar year 2026. The presenters will discuss and demonstrate the current Longitudinal Assessment Program (LAP) for ABPM diplomates that has replaced the 10-year high-stakes recertification examination.

Learning Objectives:

Learners will be able to:

- Identify benefits of continuing certification for physicians in practice.
- Discuss the ABPM's transition from maintenance of certification (MOC) to an innovative and flexible Continuing Certification Program (CCP) in Addiction Medicine through ABPM.
- Recognize requirements for continuing certification in Addiction Medicine through ABPM.

Disclosure(s):

Michael F. Weaver, MD, DFASAM: No financial relationships to disclose

Christopher J. Ondrula, JD: No financial relationships to disclose

Mia Katzenberger: No financial relationships to disclose

Opening General Session – Resilience & Navigating Uncertainty

Friday, April 24, 2026

8:30 AM - 9:45 AM PT

Location: Seaport Ballroom, Level 2

Presenter(s)

[Michael Ungar, PhD](#)

Canada Research Chair in Child, Family and Community Resilience
Dalhousie University
Hammonds Plains, Nova Scotia

Moderator(s)

[Stephen M. Taylor, MD, MPH, DFAPA, DFASAM](#)

Chief Medical Officer
Pathway Healthcare Services, LLC
Jonesboro, Georgia

Disclosure(s):

Michael Ungar, PhD: No disclosure to display

Artificial Intelligence and the Future of Addiction Medicine

Friday, April 24, 2026

10:45 AM - 12:00 PM PT

Location: Seaport Ballroom, Level 2

Presenter(s)

[Sara J. Polley, MD, FAPA, FASAM](#)

Child, Adolescent, Adult, Addiction Psychiatrist
Vantage Mental Health
Minneapolis, Minnesota

Emily Brunner, MD

Supervising physician consultant
Hazelden Betty Ford Foundation
Lake Elmo, Minnesota

Michael Eiden, PhD, LCSW, LCADC, CSAT, CCS

Therapist
Eiden Integrative Counseling
Milwaukie, Oregon

Daniel Kaufmann, PhD, LPC, LMHC

Director of Gaming Services & Program Development | Associate Professor
Kindbridge Behavioral Health | Grand Canyon University
Orlando, Florida

Explore how artificial intelligence is transforming addiction medicine—from predicting risk and personalizing treatment to supporting recovery—while uncovering its risks for mental health and addictive use. Learn practical strategies to integrate AI safely, ethically, and equitably into clinical care. This session offers clinicians actionable insights to harness technology without compromising human connection.

Learning Objectives:

Learners will be able to:

- Describe current and emerging applications of artificial intelligence across prevention, diagnosis, treatment, and recovery in addiction care.
- Evaluate the evidence base, benefits, and limitations of artificial intelligence tools used in clinical and telehealth settings, including implications for equity and patient engagement.
- Identify risks of addictive use of artificial intelligence, its mental health impacts, and strategies for safe and ethical integration of AI tools into clinical addiction care.

Disclosure(s):

Sara J. Polley, MD, FAPA, FASAM: No financial relationships to disclose

Emily Brunner, MD: No financial relationships to disclose

Michael Eiden, PhD, LCSW, LCADC, CSAT, CCS: No financial relationships to disclose

Daniel Kaufmann, PhD, LPC, LMHC: No financial relationships to disclose

Effectiveness of Extended-Release Buprenorphine in OUD: Results from NIDA CTN Studies

Developed in Collaboration with the National Institute of Drug Abuse

Friday, April 24, 2026

10:45 AM - 12:00 PM PT

Location: Gaslamp, Level 2

Presenter(s)

Geetha A. Subramaniam, MD, DLFAPA, DFAACAP

Deputy Director
NIDA
North Bethesda, Maryland

Michelle Lofwall, MD, MS, DFAPA, DFASAM

Professor/Medical Director of First Bridge and Straus Clinics/Bell Alcohol and Addictions Chair
University of KY College of Medicine, Center on Drug and Alcohol Research
Lexington, Kentucky

Gail D'Onofrio, MD, MS, FACEM, FASAM

Albert E. Kent Professor of Emergency Medicine
Yale School of Medicine
Fairfield, Connecticut

Presentations from two large, HEAL-funded, NIDA CTN multi-site trials: 1) The Medication Treatment for Opioid-dependent Expecting Mothers (MOMs) Trial showed that participants who received extended-release buprenorphine had significantly higher illicit opioid abstinence during pregnancy and was non-inferior postpartum. 2) The Emergency Department-Initiated buprenorphine and VALIDaTION Network Trial (ED-INNOVATION) study showed successful implementation of extended release (XR)-BUP in ED patients with untreated OUD; and that it was superior to sublingual (SL) BUP in linkage to care post-ED induction.

Learning Objectives:

Learners will be able to:

- Upon completion, the participant will be able to describe the role of extended-release buprenorphine in the management of pregnant and post-partum women with OUD
- Upon completion the participant will be able to identify patients with OUD eligible for successful induction on extended-release buprenorphine when they present at ED settings
- Upon completion the participant will be able to discuss the evidence for the safe and effective use of extended-release buprenorphine in two high risk populations

Disclosure(s):

Geetha A. Subramaniam, MD, DLFAPA, DFAACAP: No financial relationships to disclose

Michelle Lofwall, MD, MS, DFAPA, DFASAM: No disclosure to display

Gail D'Onofrio, MD, MS: No financial relationships to disclose

Helping Patient Care Make Cent\$: Billing and Coding Strategies for Addiction Medicine

Friday, April 24, 2026

10:45 AM - 12:00 PM PT

Location: Harbor A-C, Level 2

Presenter(s)

Darve Robinson, MD

Assistant Professor of Medicine
Cooper University Hospital
Camden, New Jersey

Rachel Haroz, MD

Center Head, Cooper Center for Healing
Cooper University Health Care
Camden, New Jersey

Jeffrey Jaeger, MD, FASAM

Professor of Clinical Medicine
Cooper University Health Care, Cooper Medical School of Rowan University
Philadelphia, Pennsylvania

Non-presenting author(s)

- SH

Susan Holzberg, n/a

Director of Financial Operations and Revenue
Cooper University Hospital
Camden, New Jersey

Greg Langan, DHSc, LSW, MPH

Administrative Director
Cooper University Health Care
Camden, New Jersey

This dynamic workshop empowers academic addiction medicine programs to forge a sustainable financial future! Discover how to master billing and coding, strategically partner with insurers, and harness new CMS guidelines to amplify clinical efforts – ultimately broadening access to life-saving addiction care. Expect engaging presentations, interactive exercises, and practical resources to ensure you leave ready to implement change.

Learning Objectives:

Learners will be able to:

- Create a stakeholder engagement strategy for state Medicaid and Commercial insurers to expand billing and funding opportunities for people who use drugs and alcohol
- Analyze current clinical documentation for opportunities for growth in term billing and coding strategies including new billing pathways established by CMS in CY 2025
- Develop an implementation and educational strategy for billing and coding innovation amongst clinical providers

Disclosure(s):

Darve Robinson, MD: No financial relationships to disclose

Rachel Haroz, MD: No financial relationships to disclose

Jeffrey Jaeger, MD: No financial relationships to disclose

Greg Langan, DHSc, LSW, MPH: No financial relationships to disclose

Housing is Health: A Health System's Approach to Housing and Community Partnership

Friday, April 24, 2026

10:45 AM - 12:00 PM PT

Location: Regatta, Level 4

Presenter(s)

Juleigh Nowinski Konchak, MD MPH FASAM

System Director, SUD Services, Behavioral Health Service Line
Cook County Health
Chicago, Illinois

Lydia Karch, MPH

Research Program Grant Coordinator
Cook County Health
Chicago, Illinois

Chante Gamby, LCSW

Housing Director
Cook County Health
Berwyn, Illinois

Vauna Hernandez, NCRS, CPRS

Executive Director
Phoenix Recovery Support Services
Chicago, Illinois

Cayse M. Powell, MD, MPH

Fellow, Preventive Medicine and Public Health
Cook County Health/Northwestern University Feinberg School of Medicine
Chicago, Illinois

Non-presenting author(s)

Keiki Hinami, MD MS

Attending Physician
Cook County Health
Chicago, Illinois

Sonia Roxo, BSN, RN

SUD Registered Nurse
Cook County Health
Melrose Park, Illinois

Substance use is prevalent among persons experiencing homelessness, and this session aims to present a multi-pronged approach to addressing housing insecurity in an urban safety net healthcare system. We will discuss implementation barriers and facilitators and operational wins and pitfalls, with a focus on individuals using substances. The challenges and successes of these interventions will be highlighted, so attendees may use them as models to explore in their own communities.

Learning Objectives:

Learners will be able to:

- Upon completion, participants will be able to describe the prevalence of substance use among homeless populations, with substance use as potentially both causal and a consequence of homelessness.
- Upon completion, participants will be able to define medical respite and permanent supportive housing, and their roles in a comprehensive strategy to end homelessness.
- Upon completion, participants will be able to explain the role of both traditional recovery homes and non-traditional recovery-oriented transitional housing programs for individuals with a substance use disorder.

Disclosure(s):

Juleigh Nowinski Konchak, MD MPH FASAM: No financial relationships to disclose

Lydia Karch, MPH: No financial relationships to disclose

Chante Gamby, LCSW: No financial relationships to disclose

Vauna Hernandez, NCRS, CPRS: No financial relationships to disclose

Keiki Hinami, MD MS: No financial relationships to disclose

Cayse M. Powell, MD, MPH: No financial relationships to disclose

Sonia Roxo, BSN, RN: No financial relationships to disclose

Implementing Hospital and ED SUD Care: Translating ASAM Guidance into Action

Friday, April 24, 2026

10:45 AM - 12:00 PM PT

Location: Harbor G-I, Level 2

Presenter(s)

Sarah E. Wakeman, MD, FASAM

Medical Director, Substance Use Disorder
Mass General Brigham
Charlestown, Massachusetts

Honora Englander, MD

Professor; Founding Director, Improving Addiction Care Team
Oregon Health & Science University
Portland, Oregon

Itai Danovitch, MD, MBA, DFAPA, DFASAM

Professor and Chair
Cedars-Sinai
Los Angeles, California

Hospitals and emergency departments represent critical opportunities to address substance use disorders. This interactive workshop will share practical models, strategies, and tools from ASAM's new implementation guide to support evidence-based care in hospital/ED settings. Participants will engage in case-based learning and small group discussions to identify solutions for overcoming barriers such as stigma, financing, and workforce limitations.

Learning Objectives:

Learners will be able to:

- Learning Objective 1: Upon completion, participants will be able to describe ASAM's core competencies for hospital and ED-based SUD care.
- Learning Objective 2: Upon completion, participants will be able to analyze barriers and facilitators to implementing SUD care in acute settings.
- Learning Objective 3: Upon completion, participants will be able to design an interprofessional implementation strategy for hospital-based SUD services.

Disclosure(s):

Sarah E. Wakeman, MD: No disclosure to display

Honora Englander, MD: No financial relationships to disclose

Itai Danovitch, MD, MBA, DFASAM, DFAPA: No disclosure to display

Improving Methadone Dose Confirmation: Innovative Approaches and Challenges of CFR Part 2

Friday, April 24, 2026

10:45 AM - 12:00 PM PT

Location: Balboa, Level 2

Presenter(s)

[William M. Garneau, MD, MPH, MHS](#)

Assistant Professor of Medicine
Johns Hopkins School of Medicine
Baltimore, Maryland

[Malik Burnett, MD, MBA, MPH](#)

Medical Director
REACH Health Services
Laurel, Maryland

[Sophia Peng, MD FASAM](#)

Assistant Professor of Medicine
Rush University Medical Center
chicago, Illinois

[Aaron Ferguson, BSW](#)

Harm Reduction Coordinator - Leadership Team-Methadone Liaison
National Survivors Union - Community Medical Services
Austin, Texas

Non-presenting author(s)

[Maia Gottlieb, MPH](#)

Behavioral Health Lead
CRISP
Washington, District of Columbia

Nicole M. Gastala, MD, MS

Chief of Integrated Behavioral Health and Addiction
UI Health Mile Square Health Center - University of Illinois Chicago
Chicago, Illinois

Corrina Klein, B.A.

MD/MPH Student
Johns Hopkins University
Baltimore, Maryland

Join us for an engaging and interactive workshop that addresses the opportunities for integration of methadone dosage verification within health information exchange systems. Participants will explore real-world challenges and collaborative solutions to enhance continuity of care for individuals transitioning between hospital and community treatment, ultimately improving health outcomes and addressing disparities in opioid treatment.

Learning Objectives:

Learners will be able to:

- Upon completion, participant will be able to describe the legal status of methadone treatment data for clinical use
- Upon completion, participant will be able to evaluate innovative approaches to improve continuity of care for methadone treatment across health care settings and develop solutions to improve care at a local level
- Upon completion, participant will be able to appraise the clinical benefits and unintended legal consequences of OTP integration with PDMP data.

Disclosure(s):

William M. Garneau, MD MPH MHS: No disclosure to display

Malik Burnett, MD, MBA, MPH: No financial relationships to disclose

Sophia Peng, MD FASAM: No financial relationships to disclose

Maia Gottlieb, MPH: No financial relationships to disclose

Nicole M. Gastala, MD, MS: No financial relationships to disclose

Corrina Klein, B.A.: No financial relationships to disclose

On the Rocks: Fixing Our Fractured Alcohol Policies

Friday, April 24, 2026

10:45 AM - 12:00 PM PT

Location: Coronado DE, Level 4

Presenter(s)

Marlene C. Lira, MPH

DrPH Candidate
Johns Hopkins Bloomberg School of Public Health
Santa Fe, New Mexico

Marissa Esser, PhD, MPH

Founder and Principal Consultant
Esser Public Health Consulting, LLC
Peachtree Corners, Georgia

Mike Marshall

C.E.O.
U.S. Alcohol Policy Alliance
Portland, Oregon

Non-presenting author(s)

Cara A. Poland, MD, MEd, DFASAM

Associate Professor
Michigan State University
Michigan State University
Alto, Michigan

Regina LaBelle, JD

Professor, Director
Georgetown University
Washington, District of Columbia

Lauren Hendy, PhD

Research Analyst/Writer
Workit Health
Ann Arbor, Michigan

Alcohol-related harm is rising, yet policy solutions remain underused and fragmented. This dynamic, hands-on workshop equips clinicians, researchers, and public health professionals with proven strategies to influence alcohol policy through effective messaging, advocacy tools, and real-world examples. Attendees will leave with actionable skills to drive meaningful change in their communities to improve health and well-being.

Learning Objectives:

Learners will be able to:

- Upon completion, participants will be able to analyze and apply evidence-based alcohol policy strategies to real-world advocacy scenarios.
- Upon completion, participants will be able to identify concrete ways in which clinicians, researchers, and other addiction professionals can engage in policy advocacy.
- Upon completion, participants will be able to develop and deliver concise, persuasive policy messages using storytelling and media techniques.

Disclosure(s):

Marlene C. Lira, MPH: No financial relationships to disclose

Marissa Esser, PhD, MPH: No financial relationships to disclose

Mike Marshall: No financial relationships to disclose

Cara A. Poland, MD, MEd, DFASAM: No financial relationships to disclose

Regina LaBelle, JD: No disclosure to display

Perinatal Alcohol Use Disorder: Management Considerations Across the Care Continuum

Friday, April 24, 2026

10:45 AM - 12:00 PM PT

Location: Coronado A-C, Level 4

Presenter(s)

[Niraj R. Chavan, MD, MPH, FACOG, FASAM](#)

Associate Professor, Fellowship Director
Saint Louis University / SSM Health
Saint Louis, Missouri

Sonja Williams, DO, FACOOG, FASAM

Medical Director
Cullman AL
Cullman, Alabama

Maria Manriquez, MD, FACOG, FASAM

Professor, Associate Fellowship Director
University of Arizona, College of Medicine - Phoenix
Phoenix, Arizona

This session at the 2026 ASAM annual conference will be structured as a workshop to allow active audience engagement, small group discussion, simulation based and case-based learning centered on addressing alcohol use in pregnancy and postpartum, anchored in evidence-based and practice-informed guidelines pertaining to the management of alcohol use disorder in perinatal populations. This session will therefore address a critical knowledge and practice gap, as it pertains to the skill set needed for managing perinatal alcohol use disorder.

Learning Objectives:

Learners will be able to:

- Discuss the approach to screening for alcohol use disorder among pregnant and parenting persons and demonstrate the use of brief intervention to address this clinically.
- Recognize the clinical presentation in cases of acute alcohol intoxication and withdrawal and articulate the approach to evaluation and management in the inpatient setting
- Describe evidence informed strategies for long term outpatient management using pharmacotherapy most suited to the pregnancy and postpartum landscape

Disclosure(s):

Niraj R. Chavan, MD, MPH, FACOG, FASAM: No disclosure to display

Sonja Williams, DO, FACOOG, FASAM: No disclosure to display

Maria Manriquez, MD, FACOG, FASAM: No financial relationships to disclose

Pharmacologic Innovations in Alpha-2 Agonist Withdrawal Management in EDs and ICUs

Friday, April 24, 2026

10:45 AM - 12:00 PM PT

Location: Harbor D-F, Level 2

Presenter(s)

Jeanmarie Perrone, MD

Director, Center for Addiction Medicine and Policy
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Michael J. Lynch, MD FACEP FACMT

Associate Professor, Senior Medical Director
UPMC and UPMC Health Plan
Pittsburgh, Pennsylvania

Joseph D'Orazio, MD, FAAEM, FACMT, FASAM, FCPP

Associate Professor of Emergency Medicine
Cooper Medical School of Rowan University
Philadelphia, Pennsylvania

Brendan Hart, MD, PhD

Associate Professor of Clinical Emergency Medicine
Temple University
Philadelphia, Pennsylvania

Kory S. London, MD

Associate Professor, Medical Director, Addiction Provider
Thomas Jefferson University
Philadelphia, Pennsylvania

Andrew Otte, PhD

Research Associate Professor
Purdue University
West Lafayette, Indiana

Join a multidisciplinary panel of experts in emergency medicine, toxicology, addiction medicine and pharmacologists as they explore the evolving landscape of illicit drug adulteration—focusing on the emergence of medetomidine in the fentanyl supply. This session will highlight clinical challenges in diagnosing and managing acute toxicity and withdrawal, with insights into its growing impact on healthcare systems and substance use treatment infrastructure.

Learning Objectives:

Learners will be able to:

- Identify toxico-surveillance sources to suggest that medetomidine is contributing to an emerging regional overdose phenomenon.
- Describe the characteristics and pharmacologic management of a medetomidine withdrawal syndrome
- List emerging strategies and innovations considered to mitigate the medetomidine withdrawal syndrome.

Disclosure(s):

Jeanmarie Perrone, MD: No financial relationships to disclose

Michael J. Lynch, MD FACEP FACMT: No financial relationships to disclose

Joseph D'Orazio, MD, FAAEM, FACMT, FASAM, FCPP: No financial relationships to disclose

Brendan Hart, MD, PhD: No financial relationships to disclose

Kory S. London, MD: No financial relationships to disclose

Andrew Otte, PhD: No financial relationships to disclose

Unprescribed Influence: Navigating Benzodiazepine Tapering in the Age of Social Media

Friday, April 24, 2026

10:45 AM - 12:00 PM PT

Location: America's Cup, Level 4

Presenter(s)

[Kristina Reinstatler, PharmD, MBA, BCPP](#)

Clinical Pharmacy Specialist
UC Health
Cincinnati, Ohio

[Daniel Bebo, MD](#)

Clinical Director
UC Health
Cincinnati, Ohio

Learn to build an interdisciplinary benzodiazepine taper clinic focused on safe, patient-centered care. This session equips clinicians to provide supportive guidance and counter social media misinformation as patients move through the tapering process.

Learning Objectives:

Learners will be able to:

- Describe strategies for developing a benzodiazepine tapering program tailored to diverse patient needs.
- Apply clinical guidance documents into individualized care plans for patients seeking benzodiazepine tapering.
- Evaluate social media narratives about benzodiazepines and construct patient-centered communication strategies.

Disclosure(s):

Kristina Reinstatler, PharmD, MBA, BCPP: No financial relationships to disclose

Daniel Bebo, MD: No financial relationships to disclose

Advanced Management of Alcohol Withdrawal: Case-Based, Evidence-Informed Solutions

Friday, April 24, 2026

1:30 PM - 2:45 PM PT

Location: Seaport Ballroom, Level 2

Presenter(s)

[Tessa L. Steel, MD, MPH](#)

Assistant Professor
University of Washington
Seattle, Washington

- MW

[Melissa B. Weimer, DO, MCR, DFASAM](#)

Physician/Associate Professor of Medicine (General Medicine) and of Epidemiology (Chronic Diseases)
Yale School of Medicine
New Haven, Connecticut

[Ryan JJ Buckley, MD, MPH](#)

Assistant Professor
Yale School of Medicine
New Haven, Connecticut

Managing severe and resistant alcohol withdrawal syndrome (AWS) requires rapid decision-making, nuanced clinical judgment, and coordinated care across multiple disciplines. This advanced, case-based session prepares clinicians to assess and treat complex AWS presentations using validated tools and current treatment guidelines. Attendees will explore pharmacologic strategies, escalation protocols, and approaches for special populations, including older adults, pregnant patients, and those with co-occurring conditions. The session emphasizes practical application to improve outcomes in high-risk clinical scenarios.

Learning Objectives:

Learners will be able to:

- Analyze complex patient presentations using validated assessment tools (e.g., PAWSS, CIWA-Ar, MINDS, RASS) to guide risk stratification and individualized treatment planning.
- Apply pharmacologic and supportive care strategies to the management of severe and resistant alcohol withdrawal in various clinical settings.
- Select appropriate screening, diagnostic, and treatment strategies to overcome challenges with complex patient cases of AWS.

Disclosure(s):

Tessa L. Steel, MD, MPH: No financial relationships to disclose

Melissa B. Weimer, DO, MCR, DFASAM: No financial relationships to disclose

Ryan JJ Buckley, MD, MPH: No financial relationships to disclose

Bridging Barriers: 3 Jail-Based MOUD Models That Save Lives and Restore Hope

Friday, April 24, 2026

1:30 PM - 2:45 PM PT

Location: Coronado A-C, Level 4

Presenter(s)

Danae N. DiRocco, MD

Addiction Psychiatrist, Medical Director of Telepsychiatry for CHI Health
Creighton University School of Medicine, CHI Health
Rocky River, Ohio

Eric Weintraub, MD

MD
University of Maryland
Towson, Maryland

Hendree E. Jones, PhD, LP

Professor
University of North Carolina at Chapel Hill
Carrboro, North Carolina

Renita J. Bartley, Pharm D, CDCA

Pharmacy Specialist - Corrections
MetroHealth Hospital - Correctional Medicine
Sagamore Hills, Ohio

Discover how three innovative MOUD models, from telehealth in rural settings to specialized programs for women, are improving care and outcomes for those with opioid use disorder in jails. This interactive workshop provides addiction treatment professionals with practical tools to overcome common barriers, foster collaboration with correctional staff, and build sustainable, life-saving programs behind and beyond the walls.

Learning Objectives:

Learners will be able to:

- Evaluate and differentiate three evidence-based MOUD delivery models in jail settings, including in-person, telehealth, and programs tailored to pregnant/parenting women, to inform best practices in correctional addiction care.
- Identify practical solutions to common challenges in jail-based MOUD programs, such as diversion, withdrawal management, and reentry planning, to enhance treatment continuity and patient outcomes.

- Demonstrate strategies for building collaborative relationships with correctional staff by aligning shared values and goals, to support successful and sustainable MOUD implementation within carceral systems.

Disclosure(s):

Danae N. DiRocco, MD: No financial relationships to disclose

Eric Weintraub, MD: No financial relationships to disclose

Hendree E. Jones, PhD, LP: No financial relationships to disclose

Renita J. Bartley, Pharm D, CDCA: No financial relationships to disclose

Collaborative Care for OUD with Co-Occurring Mental Disorders in Safety-Net Primary Care

Friday, April 24, 2026

1:30 PM - 2:45 PM PT

Location: Coronado DE, Level 4

Presenter(s)

[Colleen M. McCullough, MPA](#)

Data Scientist
RAND
Santa Monica, California

[Grace M. Hindmarch, BSPH](#)

Research Assistant and PhD Student in Health Policy
RAND and UCLA
Santa Monica, California

[Alex R. Dopp, PhD](#)

Senior Scientist
RAND
Santa Monica, California

[Brian Hurley, MD, M.B.A., FAPA, DFASAM](#)

Medical Director
Los Angeles County Department of Public Health
Los Angeles, California

Non-presenting author(s)

Katherine Watkins, MD, MSHS

Senior Scientist
RAND Corporation
Santa Monica, California

This focus session will describe the implementation, patient and provider experiences, and patient outcomes of a clinical trial of collaborative care for patients with opioid use disorders co-occurring with mental disorders in primary care safety-net settings. Combining didactic presentations, audience discussion, and a structured conversation facilitation method, the session will provide lessons learned from a completed trial, as well as a path forward for practitioners looking to implement collaborative care in their practice.

Learning Objectives:

Learners will be able to:

- Define collaborative care and describe how it was adapted to treat opioid use disorder co-occurring with mental disorders (depression and/or PTSD)
- Describe findings from a recent completed trial of collaborative care for patients with opioid use disorder co-occurring with mental disorders, including important considerations around patient characteristics.
- Identify key resources and activities for implementing collaborative care with diverse patient populations and primary care settings, and how the information from the session could be applied in practice, policy, and future research

Disclosure(s):

Colleen M. McCullough, MPA: No financial relationships to disclose

Grace M. Hindmarch, BSPH: No financial relationships to disclose

Alex R. Dopp, PhD: No financial relationships to disclose

Brian Hurley, MD, M.B.A., FAPA, DFASAM: No financial relationships to disclose

Katherine Watkins, MD, MSHS: No financial relationships to disclose

Drug Testing: Practical Interpretation Beyond the Urine Cup

Friday, April 24, 2026

1:30 PM - 2:45 PM PT

Location: Harbor D-F, Level 2

Presenter(s)

JoAn Laes, MD

Addiction Physician
Allina
Minneapolis, Minnesota

Stephanie T. Weiss, MD, PhD, FASAM, FAACT

Staff Research Physician
NIDA/NIH
National Institute on Drug Abuse Intramural Research Program
Baltimore, Maryland

Evan S. Schwarz, MD, FASAM

Clinical Professor of Emergency Medicine, Medical Toxicology Fellowship Director
UCLA
Los Angeles, California

Robert Cole Pueringer, MD

Addiction Medicine, Medical Toxicology; Medical Director of Substance Use and Addiction Care Program
Essentia Health
Duluth, Minnesota

Non-presenting author(s)

Jeremiah D. Fairbanks, DO

Physician
Allina
Inver Grove Heights, Minnesota

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM

Director of Addiction Medicine
University of Rochester Medical Center
University of Rochester School of Medicine & Dentistry
Rochester, New York

Drug testing plays a critical role in clinical care, monitoring, and the broader social systems that intersect with addiction medicine. Yet many clinicians lack training in the interpretation, regulatory boundaries, and practical implications of testing. This leads to misinterpretation and inappropriate testing potentially leading to harm. This session addresses how to interpret, properly use, and apply drug testing results responsibly. Participants will learn to recognize common misinterpretations, avoid unnecessary testing, interpret testing from alternative matrices, and align with practice standards.

Learning Objectives:

Learners will be able to:

- Interpret the limitations of urine, oral fluid, hair, and sweat testing in various settings.
- Recognize how misinterpretation of confirmatory or quantitative results may lead to clinical or legal harm, and identify safeguards to prevent misuse.
- Evaluate the current role of CLIA-waived and point-of-care tests, including regulatory considerations, emerging technologies, and public health implications.

Disclosure(s):

JoAn Laes, MD: No financial relationships to disclose

Stephanie T. Weiss, MD, PhD, FASAM, FAACT: No financial relationships to disclose

Evan S. Schwarz, MD, FASAM: No financial relationships to disclose

Robert Cole Pueringer, MD: No financial relationships to disclose

Jeremiah D. Fairbanks, DO: No financial relationships to disclose

Expanding Access to Adolescent Substance Use Disorder Treatment

Friday, April 24, 2026

1:30 PM - 2:45 PM PT

Location: Gaslamp, Level 2

Presenter(s)

[William Coe, MD, MPH](#)

Psychiatrist
NYU Grossman School of Medicine
Brooklyn, New York

Jordan P. Davis, PhD

Clinical Assistant Professor
NYU Langone Child Study Center
New York, New York

Pantea Farahmand, MD

Assistant Clinical Professor of Child and Adolescent Psychiatry and Addiction Psychiatry
NYU Langone
Jersey City, New Jersey

Non-presenting author(s)

- KL

Katarzyna Liwski, DO

Clinical Assistant Professor of Child and Adolescent Psychiatry Clinical Assistant Professor of Psych
NYU Langone
New York, New York

Frustrated by our health care system? Ever thought about how you might implement a new program or service within your clinic or hospital? Have you tried, only to be met with resistance? In this focus session, we will review gaps in adolescent SUD treatment, introduce two novel programs that were successfully developed by the presenters, and generalize knowledge and insight from these programs to help you effect change in your workplace and communities.

Learning Objectives:

Learners will be able to:

- Describe recent trends in adolescent substance use, existing evidence-based treatment modalities, and current gaps in care specific to the adolescent population
- Identify common logistical, financial, and clinical challenges of developing adolescent SUD treatment programs, as well as strategies to overcome these barriers
- Explore ways of implementing adolescent SUD services (or other new programs) within their workplace and communities

Disclosure(s):

William Coe, MD, MPH: No financial relationships to disclose

Jordan P. Davis, PhD: No financial relationships to disclose

Pantea Farahmand, MD: No financial relationships to disclose

Low-Threshold Injectable PrEP in People Who Use Drugs

Friday, April 24, 2026

1:30 PM - 2:45 PM PT

Location: Regatta, Level 4

Presenter(s)

Ethan Cowan, MD, MS

Professor, Emergency Medicine
RUTGERS THE STATE UNIV OF NEW JERSEY
Newark, New Jersey

Ruchi M. Fitzgerald, MD, FAAFP FASAM

Service Chief, Addiction Medicine Consult Service
PCC Community Wellness Center-MacNeal Hospital-Loyola Univ
Rush University
Chicago, Illinois

- FT

Francesco Tani, DO

Physician
Howard Brown Health // PCC Community Wellness
Chicago, Illinois

Cayse M. Powell, MD, MPH

Fellow, Preventive Medicine and Public Health
Cook County Health/Northwestern University Feinberg School of Medicine
Chicago, Illinois

Long-acting injectable PrEP represents a breakthrough in HIV prevention for people who use drugs, offering new opportunities for low-threshold, integrated care. This session combines didactic updates with real-world implementation lessons from leading programs across addiction medicine and harm reduction to help participants translate innovation into clinical practice.

Learning Objectives:

Learners will be able to:

- Describe the pharmacology, dosing schedules, efficacy and safety of long-acting injectable PrEP agents (cabotegravir and lenacapavir).
- Identify key barriers and facilitators to PrEP access and uptake among people who use drugs, including structural, social and system-level factors.
- Discuss real-world models for integrating low-threshold injectable PrEP into harm-reduction and addiction-medicine settings (including pregnant/postpartum populations).

Disclosure(s):

Ethan Cowan, MD, MS: No disclosure to display

Ruchi M. Fitzgerald, MD, FAAFP FASAM: No financial relationships to disclose

Francesco Tani, DO: No financial relationships to disclose

Cayse M. Powell, MD, MPH: No financial relationships to disclose

Opioid Angst in the Pain Clinic: New Multisociety Consensus Guidelines

Friday, April 24, 2026

1:30 PM - 2:45 PM PT

Location: Harbor A-C, Level 2

Presenter(s)

[Gregory D. Rudolf, MD](#)

physician
Swedish Health Services
Seattle, Washington

[Lynn Kohan, MD](#)

Division Chief/, Program director
University of Virginia
Charlottesville, Virginia

Mark C. Bicket, MD, PhD, FASA

Associate Professor/Co-Director, Overdose Prevention Engagement Network
University of Michigan
Ann Arbor, Michigan

Most medical practitioners encounter patients with chronic pain who have experienced opioid-related challenges. The newly published ASRA Consensus Guideline outlines best practices for pain specialists in managing these patients. Whether you work in a pain specialty setting, or in primary care, physiatry, sports medicine, neurology, rheumatology, or psychiatry, the guideline's key statements and recommendations are pertinent to your practice. The session is structured around a longitudinal, interactive clinical case study, with guideline contents embedded throughout the discussion of the case.

Learning Objectives:

Learners will be able to:

- 1. Differentiate between OUD, CPOD, and physiologic dependence, and outline diagnostic and therapeutic implications in the chronic pain setting.
- 2. Design treatment plans incorporating buprenorphine or other MOUD for patients with coexisting pain and OUD, including initiation, maintenance, and perioperative considerations
- 3. Interpret and respond to urine drug screen findings and other objective screening for aberrant behaviors in the context of prescribed opioids or MOUD, using a patient-centered, evidence-based framework.

Disclosure(s):

Gregory D. Rudolf, MD: No financial relationships to disclose

Lynn Kohan, MD: No disclosure to display

Mark C. Bicket, MD, PhD, FASA: No disclosure to display

Peer Recovery Coaching to Enhance MOUD Outcomes

Friday, April 24, 2026

1:30 PM - 2:45 PM PT

Location: Balboa, Level 2

Presenter(s)

Kevin R. Wenzel, PhD

Director of Research
Maryland Treatment Centers/Mountain Manor
Baltimore, Maryland

Marc Fishman, MD, FASAM

Medical Director
Maryland Treatment Centers
Johns Hopkins University School of Medicine
Baltimore, Maryland

Katie Lee, CPRS (Certified Peer Recovery Specialist)

Peer Recovery Coach
Maryland Treatment Centers
Rockville, Maryland

This session provides a summary of the application of peer recovery support services (PRSS) to enhance medication for opioid use disorder (MOUD) outcomes. Contents will include summary of the literature, presenting results of a pilot PRSS study, and hearing the perspectives and lessons learned from a multidisciplinary panel including a psychologist, certified peer support specialist, and addiction psychiatrist.

Learning Objectives:

Learners will be able to:

- Summarize the scientific support and gaps for peer recovery support services related to MOUD.
- Describe the methods and results of the recent PRSS study.
- List potential future directions for PRSS research related to enhancing MOUD outcomes.

Disclosure(s):

Kevin R. Wenzel, PhD: No disclosure to display

Marc Fishman, MD, FASAM: No disclosure to display

Katie Lee, CPRS (Certified Peer Recovery Specialist): No financial relationships to disclose

TMS for Treatment of Addiction and Its Psychiatric Comorbidities: Safety and Efficacy

Friday, April 24, 2026

1:30 PM - 2:45 PM PT

Location: America's Cup, Level 4

Presenter(s)

Hamed Ekhtiari, MD, PhD, DFISAM

Associate Professor and Division Chief
University of Texas Southwestern
Dallas, Texas

- KB

Kathleen T. Brady, MD, PhD

Professor
Medical University of South Carolina
Charleston, South Carolina

Manish K. Jha, MD

Associate Professor
UTSW
Dallas, Texas

Victor Tang, MD

Assistant Professor
University of Toronto
Toronto, Ontario

This 75-minute Focus Session explores the expanding role of repetitive transcranial magnetic stimulation (rTMS) in treating substance use disorders and comorbid depression. Led by four leading experts, the session combines evidence-based presentations, real-world case discussions, and safety-focused guidance. Attendees will gain actionable strategies to implement rTMS protocols and optimize outcomes in complex dual-diagnosis populations.

Learning Objectives:

Learners will be able to:

- Discuss patient selection, contraindications, and safety in using TMS in dual-diagnosis populations.
- Examine evolving TMS stimulation protocols (e.g., intermittent theta burst, accelerated courses) and evidence from ongoing trials for people with SUD.

- Explore clinical guidelines and decision-making frameworks for integrating rTMS into multidisciplinary addiction care.

Disclosure(s):

Hamed Ekhtiari, MD, PhD, DFISAM: No financial relationships to disclose

Manish K. Jha, MD: No disclosure to display

Victor Tang, MD: No financial relationships to disclose

Unusual Clues: Hidden Presentations of Substance Use Disorders Across Clinical Disciplines

Friday, April 24, 2026

1:30 PM - 2:45 PM PT

Location: Harbor G-I, Level 2

Presenter(s)

Omar Hassan, MD

Resident Physician
Hennepin Healthcare
Minneapolis, Minnesota

Cailean Dakota MacColl, BA, BS

Medical Student
University of Minnesota Medical School
Minneapolis, Minnesota

Ese B. Aghenta, MD, MPH, FASAM

Physician
North Memorial Hospital
Minneapolis, Minnesota

- SA

Seleipiri Iboroma Akobo, MD, MBA, MPH, FASAM

Physician
Maine Medical Center
Scaborough, Maine

Non-presenting author(s)

Charles P. Reznikoff, MD, FASAM, FACP

Associate program director, internal medicine, Associate professor of medicine
Hennepin Healthcare, University of Minnesota
Minneapolis, Minnesota

- JS

Jacob K. Smith, MD

Resident Physician
Oregon Health & Science University
Portland, Oregon

- AJ

Audrey A. Jacobsen, MD, MPH

Chair of Dermatology
Hennepin Healthcare
Minneapolis, Minnesota

Hidden clues reveal big insights. This fast-paced interactive session uses clinical vignettes and images to challenge clinicians to identify overlooked signs of substance use, including the uncertainties inherent to assessing adolescent substance use, dermatologic manifestations of SUDs in people of color, and consequential nutritional deficits occurring in alcohol use disorder. Participants will gain practical, cross-disciplinary skills to recognize and diagnose subtle signs of addiction in patients and to integrate culturally informed, equitable care into their practice.

Learning Objectives:

Learners will be able to:

- Apply an adolescent-specific framework to assess and manage substance use disorders in adolescents and young adults, with a focus on immigrant stress and acculturation
- Recognize and manage dermatologic manifestations of substance use disorders across a variety of skin tones

- Identify and correct nutritional deficits in people with substance use disorders by interpreting the signs and symptoms of those deficits

Disclosure(s):

Omar Hassan, MD: No financial relationships to disclose

Cailean Dakota MacColl, BA, BS: No financial relationships to disclose

Ese B. Aghenta, MD, MPH, FASAM: No financial relationships to disclose

Seleipiri Iboroma Akobo, MD, MBA, MPH, FASAM: No financial relationships to disclose

Charles P. Reznikoff, MD, FASAM, FACP: No financial relationships to disclose

Audrey A. Jacobsen, MD, MPH: No financial relationships to disclose

Annual Review of Addiction Medicine: Highest Impact Publications 2025-26

Friday, April 24, 2026

3:15 PM - 4:30 PM PT

Location: Seaport Ballroom, Level 2

Presenter(s)

[Sarah E. Wakeman, MD, FASAM](#)

Medical Director, Substance Use Disorder
Mass General Brigham
Charlestown, Massachusetts

- JL

[Joshua D. Lee, MD](#)

Professor
NYULH
New York, New York

This engaging focus session will review the highest impact papers in the field of addiction medicine from the past year, focusing on papers that are high impact AND update practice across the most relevant and widely discussed trends in our field. Striving to be relevant to the busy clinician and available as teaching material, the presenters critically review the recent biggest articles spanning addiction neurobiology, pharmacology, intoxication and withdrawal, screening and diagnosis, treatment, mutual help, and special topics and populations.

Learning Objectives:

Learners will be able to:

- Detail the highest impact article in addiction medicine from the past year.
- Describe innovative strategies to starting long-acting injectable buprenorphine.
- Demonstrate understanding of the most relevant topics in addiction medicine from the past year, including epidemiological trends and practice changing clinical trials.

Disclosure(s):

Sarah E. Wakeman, MD: No disclosure to display

Joshua D. Lee, MD: No disclosure to display

Clinical Insights on Emerging Misuse of Performance and Image Enhancing Drugs

Friday, April 24, 2026

3:15 PM - 4:30 PM PT

Location: Harbor D-F, Level 2

Presenter(s)

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM

Director of Addiction Medicine
University of Rochester Medical Center
University of Rochester School of Medicine & Dentistry
Rochester, New York

Jeffrey Brent, MD, PhD,

Distinguished Clinical Professor
University of Colorado
Aurora, Colorado

Stephanie T. Weiss, MD, PhD, FASAM, FAACT

Staff Research Physician
NIDA/NIH
National Institute on Drug Abuse Intramural Research Program
Baltimore, Maryland

Jason Kirby, DO, MBA, FASAM

Chief Medical Officer
Landmark Recovery
Franklin, Tennessee

Stephen M. Taylor, MD, MPH, DFAPA, DFASAM

Chief Medical Officer
Pathway Healthcare Services, LLC
Jonesboro, Georgia

This interactive workshop explores the expanding use of Performance and Image Enhancing Drugs (PIEDs)—from peptides and testosterone to GLP-1 agonists—across athletic, wellness, and anti-aging settings. Participants will review pharmacologic mechanisms, psychosocial drivers, and addiction parallels, applying DEI principles to understand gender, cultural, and socioeconomic influences on access and stigma. Through case-based discussion and polling, clinicians will gain practical strategies for screening, counseling, and managing patients engaged in PIED use within diverse clinical contexts.

Learning Objectives:

Learners will be able to:

- Describe the major classes, mechanisms, and health risks of commonly used Performance and Image Enhancing Drugs (PIEDs).
- Identify psychosocial and behavioral factors—such as body image, gender norms, and cultural influences—that contribute to PIED misuse and related health disparities.
- Apply evidence-based and culturally responsive strategies for screening, counseling, and managing patients who use PIEDs in both athletic and non-athletic settings.

Disclosure(s):

Jeffrey Brent, MD, PhD,: No financial relationships to disclose

Stephanie T. Weiss, MD, PhD, FASAM, FAACT: No financial relationships to disclose

Clinical Insights on Emerging Misuse of Performance and Image Enhancing Drugs

Friday, April 24, 2026

3:15 PM - 4:30 PM PT

Location: Harbor D-F, Level 2

Presenter(s)

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM

Director of Addiction Medicine
University of Rochester Medical Center
University of Rochester School of Medicine & Dentistry
Rochester, New York

Jeffrey Brent, MD, PhD,

Distinguished Clinical Professor
University of Colorado
Aurora, Colorado

Stephanie T. Weiss, MD, PhD, FASAM, FAACT

Staff Research Physician
NIDA/NIH
National Institute on Drug Abuse Intramural Research Program
Baltimore, Maryland

Jason Kirby, DO, MBA, FASAM

Chief Medical Officer
Landmark Recovery
Franklin, Tennessee

Stephen M. Taylor, MD, MPH, DFAPA, DFASAM

Chief Medical Officer
Pathway Healthcare Services, LLC
Jonesboro, Georgia

This interactive workshop explores the expanding use of Performance and Image Enhancing Drugs (PIEDs)—from peptides and testosterone to GLP-1 agonists—across athletic, wellness, and anti-aging settings. Participants will review pharmacologic mechanisms, psychosocial drivers, and addiction parallels, applying DEI principles to understand gender, cultural, and socioeconomic influences on access and stigma. Through case-based discussion and polling, clinicians will gain practical strategies for screening, counseling, and managing patients engaged in PIED use within diverse clinical contexts.

Learning Objectives:

Learners will be able to:

- Describe the major classes, mechanisms, and health risks of commonly used Performance and Image Enhancing Drugs (PIEDs).
- Identify psychosocial and behavioral factors—such as body image, gender norms, and cultural influences—that contribute to PIED misuse and related health disparities.
- Apply evidence-based and culturally responsive strategies for screening, counseling, and managing patients who use PIEDs in both athletic and non-athletic settings.

Disclosure(s):

Jeffrey Brent, MD, PhD,: No financial relationships to disclose

Stephanie T. Weiss, MD, PhD, FASAM, FAACT: No financial relationships to disclose

Considerations for Use of Addiction Medications in Adolescents with SUD

Friday, April 24, 2026

3:15 PM - 4:30 PM PT

Location: Balboa, Level 2

Presenter(s)

[Sara J. Polley, MD, FAPA, FASAM](#)

Child, Adolescent, Adult, Addiction Psychiatrist
Vantage Mental Health
Minneapolis, Minnesota

[Sandra Gomez-Luna, MD, FAPA, DFASAM](#)

Assistant Clinical Professor of Psychiatry
Yale School of Medicine
Darien, Connecticut

[Lisa R. Fortuna, MD, MPH](#)

PROFESSOR AND CHAIR
University of California Riverside
Riverside, California

This session will summarize current challenges with accessing addiction medications for adolescents with SUD. Topics will include a risk/benefit analysis of addiction medications for youth, inclusion of the family in the treatment decision-making process, strategies for expanding access to medications for adolescents, and tailoring care to developmental age and stage.

Learning Objectives:

Learners will be able to:

- Understand key considerations for a risk/benefit analysis for addiction medications for adolescents
- Understand ongoing challenges with accessing appropriate care for adolescents with SUD
- Recognize strategies for expanding access to quality adolescent SUD treatment

Disclosure(s):

Sara J. Polley, MD, FAPA, FASAM: No financial relationships to disclose

Sandra Gomez-Luna, MD, FAPA, DFASAM: No financial relationships to disclose

Lisa R. Fortuna, MD, MPH: No financial relationships to disclose

Critical Care Addiction Medicine: Considerations for Buprenorphine in Intubated Patients

Friday, April 24, 2026

3:15 PM - 4:30 PM PT

Location: Gaslamp, Level 2

Presenter(s)

[Anthony Spadaro, MD MPH](#)

Assistant Professor of Emergency Medicine
University of Pennsylvania
Jersey city, New Jersey

- JK

[Jessica J. Krueger, MD](#)

Assistant Professor in Emergency Medicine
Rutgers New Jersey Medical School
Newark, New Jersey

[Robert Cole Pueringer, MD](#)

Addiction Medicine, Medical Toxicology; Medical Director of Substance Use and Addiction Care Program
Essentia Health
Duluth, Minnesota

[Ryan JJ Buckley, MD, MPH](#)

Assistant Professor
Yale School of Medicine
New Haven, Connecticut

Addiction medicine consult services may be consulted to assist in the management of critically ill patients with opioid use disorder (OUD) who are intubated in the intensive care unit (ICU). There are no clear guidelines for how or when to best initiate buprenorphine in intubated patients. In this session, attendees will discuss the ethics and practice of starting buprenorphine in intubated patients and will include considerations of patient autonomy, patient selection, and dose and route of buprenorphine administration.

Learning Objectives:

Learners will be able to:

- Reflect on the ethics principles that may guide the decision to initiate patients in the ICU on buprenorphine
- Update protocols for an addiction medicine consult service for taking care of patients in the ICU with OUD
- Summarize the different treatment approaches to patients with OUD in the ICU

Disclosure(s):

Anthony Spadaro, MD MPH: No financial relationships to disclose

Jessica J. Krueger, MD: No financial relationships to disclose

Robert Cole Pueringer, MD: No financial relationships to disclose

Ryan JJ Buckley, MD, MPH: No financial relationships to disclose

How Medicaid Powers Addiction Treatment: Care, Coverage and Consequences

Friday, April 24, 2026

3:15 PM - 4:30 PM PT

Location: Harbor A-C, Level 2

Presenter(s)

[Sherry Nykiel, MD](#)

Behavioral Health Medical Director
Delaware Division of Medicaid and Medical Assistance
Media, Pennsylvania

Brian Hurley, MD, M.B.A., FAPA, DFASAM

Medical Director
Los Angeles County Department of Public Health
Los Angeles, California

Medicaid finances most addiction treatment in the U.S., yet few clinicians fully understand how it works. This workshop breaks down Medicaid's structure, funding, and future under House Resolution 1 through interactive discussion and case examples from Delaware and Los Angeles County. Learn how these policies shape access, reimbursement, and outcomes in real-world addiction care.

Learning Objectives:

Learners will be able to:

- Describe how Medicaid's financing and structure influence access, reimbursement, and delivery of substance use disorder treatment across diverse systems and populations.
- Compare Delaware's integrated Medicaid model and Los Angeles County's decentralized Medical-Cal system to show how design differences affect coverage, workforce capacity, and outcomes.
- Analyze proposed policy changes under House Resolution 1 and identify advocacy strategies to sustain equitable, evidence-based addiction treatment and system stability.

Disclosure(s):

Sherry Nykiel, MD: No financial relationships to disclose

Brian Hurley, MD, M.B.A., FAPA, DFASAM: No financial relationships to disclose

Long-Acting Injectable Buprenorphine for Birthing and Parenting People with OUD

Friday, April 24, 2026

3:15 PM - 4:30 PM PT

Location: Harbor G-I, Level 2

Presenter(s)

- DS

Davida M. Schiff, MD

Associate Professor of Pediatrics
Massachusetts General Hospital
Boston, Massachusetts

Marcela C. Smid, MD MA MS

Associate professor
University of Utah Health
Salt Lake City, Utah

Melinda Ramage, FNP-BC, CARN-AP, LCAS

Director, Perinatal Substance Use Disorder Network
Governor's Institute
Asheville, North Carolina

Vania P. Rudolf, MD, MPH, FAAFP, DFASAM

Faculty Physician, Swedish Medical Center, Seattle, WA
Associate Professor, Department of Family Medicine, University of Washington
Seattle, Washington

Tricia E. Wright, MD, MS, FACOG, DFASAM

Professor and Medical Director OBIC
University of California, San Francisco
San Francisco, California

Non-presenting author(s)

Sharon Ostfeld-Johns, MD, IBCLC

Assistant Professor of Clinical Pediatrics and Internal Medicine
Yale School of Medicine
New Haven, Connecticut

Whole-person SUD care approaches health as an integrated spectrum of disease and wellness that is biological, behavioral, environmental, and social; prioritizes the individual, and efforts to address policy and economic level stressors to improve health. Treatment with LAIB formulations supports access, equity, value-based caring and optimal outcomes. Shared-decision making on choices of MOUD, "complex pain" management, toxicology and breastfeeding is a human right. The workshop will highlight opportunities for providers to be a champion for the health of their patients.

Learning Objectives:

Learners will be able to:

- Upon completion, participants will be able to describe evidence and results from CTN-0080 MOMs trial, know models of initiation of LAIB, "complex pain" management and longitudinal tools to improve care for birthing people with OUD.
- Upon completion, participants will be able to utilize ASAM tools and The 4Th criteria as a holistic guideline tool to offer person-centered care and choices for MOUD for pregnant, postpartum and parenting people with OUD.
- Upon completion, participants will be able to apply several concepts to improve skills for clinical care of newborns, utility of toxicology testing, and breastfeeding in the setting of non-prescribed opioid use and LAIB formulations.

Disclosure(s):

Davida M. Schiff, MD: No financial relationships to disclose

Marcela C. Smid, MD MA MS: No disclosure to display

Melinda Ramage, FNP-BC, CARN-AP, LCAS: No financial relationships to disclose

Vania P. Rudolf, MD, MPH, FAAFP, DFASAM: No financial relationships to disclose

Tricia E. Wright, MD, MS, FACOG, DFASAM: No financial relationships to disclose

Sharon Ostfeld-Johns, MD, IBCLC: No financial relationships to disclose

Seeking Stability in OUD Care: Person-Centered Transitions from Methadone to Buprenorphine

Friday, April 24, 2026

3:15 PM - 4:30 PM PT

Location: Coronado A-C, Level 4

Presenter(s)

Ezra Lyon, MD, FASAM

Family and Addiction Physician, Associate Clinical Director for Integrated Addiction Treatment
Bridge Community Health Clinic
Amherst, Wisconsin

- IL

Ian Latham, MD

Addiction Medicine Physician
Gundersen Health System/Emplify Health
La Crosse, Wisconsin

This interactive workshop will teach participants how to help patients transition smoothly from methadone to buprenorphine and from OTP to OBOT. Participants will learn pharmacologic strategies for transition including low-dose initiation of buprenorphine with continuation of methadone. The workshop will be a mixture of didactic material and case-based small group learning.

Learning Objectives:

Learners will be able to:

- Appraise different methods for helping patients transition from methadone to buprenorphine including low-dose initiation of buprenorphine with continuation of methadone and withdrawal from a reduced dose of methadone.
- Describe key differences between OTPs (opioid treatment programs) and OBOTs (office-based opioid treatment) in order to assist patients in choosing effective care settings.
- Advocate for patients during transitions of care by communicating effectively with clinicians and staff at OTPs and OBOTs.

Disclosure(s):

Ezra Lyon, MD, FASAM: No financial relationships to disclose

Supporting ASAM's Level 1.0 Remission Monitoring through Recovery Management Checkups

Friday, April 24, 2026

3:15 PM - 4:30 PM PT

Location: America's Cup, Level 4

Presenter(s)

Dennis P. Watson, PhD, MA, MS

Senior Research Scientist
Chestnut Health Systems
Chicago, Illinois

Michael L. Dennis, PhD

Chief Research Officer
Chestnut Health Systems
Bloomington, Illinois

Sarah Messmer, MD

Assistant Professor of Medicine and Pediatrics
University of Illinois at Chicago
Chicago, Illinois

R. Corey Waller, MD, MS, FACEP, DFASAM

Executive Advisor in Behavioral Health
Shore Capital Partners
Ann Arbor, Michigan

Non-presenting author(s)

Navdeep Kang, PsyD

Chief Quality Officer
Acadia Healthcare
Union, Kentucky

Christine E. Grella, PhD

Sr. Research Scientist
Chestnut Health Systems
Venice, California

This interactive workshop introduces Recovery Management Checkups (RMC) as a practical framework for delivering ASAM Level 1.0: Long-Term Remission Monitoring—an emerging standard that shifts addiction care from episodic treatment to sustained recovery management. Participants will be

introduced to 25 years of RMC research evidence, analyze implementation challenges, and consider real-world solutions through didactic instruction, clinical reflection, and case-based problem solving. Attendees will leave with actionable tools to support integration of RMC within their own healthcare or community settings.

Learning Objectives:

Learners will be able to:

- Describe the purpose and structure of ASAM Level 1.0: Long-Term Remission Monitoring and its alignment with chronic care principles.
- Explain the evidence base and operational components of the Recovery Management Checkups (RMC) model that support ASAM Level 1.0 remission monitoring goals.
- Identify at least two organizational barriers and corresponding solutions for adopting RMC within healthcare or community-based settings.

Disclosure(s):

Dennis P. Watson, PhD, MA, MS: No financial relationships to disclose

Michael L. Dennis, PhD: No financial relationships to disclose

Navdeep Kang, PsyD: No disclosure to display

Sarah Messmer, MD: No financial relationships to disclose

Christine E. Grella, PhD: No financial relationships to disclose

Teaching Tomorrow's Doctors: Incorporating Evidence-Based SUD Training in Medical Schools

Friday, April 24, 2026

3:15 PM - 4:30 PM PT

Location: Coronado DE, Level 4

Presenter(s)

[Rohit Chaparala, MPH](#)

Clinical Research Coordinator I
University of Alabama at Birmingham
Chelsea, Alabama

[Daryn Papenfuse, MPH](#)

Program Manager
Michigan State University
Mt. Pleasant, Michigan

Li Li, MD, PhD

Professor
University of Alabama at Birmingham
Birmingham, Alabama

Non-presenting author(s)

Cara A. Poland, MD, MEd, DFASAM

Associate Professor
Michigan State University
Michigan State University
Alto, Michigan

Madison Walsh, MS

Doctoral Student
Michigan State University
Grand Rapids, Michigan

Want to transform how future doctors treat addiction? This dynamic, hands-on workshop will show you how two medical schools are leading the charge to embed stigma-reducing, evidence-based SUD education into the core of medical training. Learn how to implement the MI CARES modular curriculum, engage stakeholders, and walk away with a process map to launch change at your own institution.

Learning Objectives:

Learners will be able to:

- Upon completion, participants will be able to analyze the impact of stigma on clinical care for patients with substance use disorders and identify strategies to address it through early medical education.
- Upon completion, participants will be able to demonstrate how to implement a modular, evidence-based SUD curriculum, such as MI CARES, across varied academic settings using real-world examples from two institutions.
- Upon completion, participants will be able to create a customized process map for curriculum adoption at participants' home institutions, incorporating stakeholder engagement, curriculum design, and sustainability planning.

Disclosure(s):

Rohit Chaparala, MPH: No financial relationships to disclose

Daryn Papenfuse, MPH: No financial relationships to disclose

Cara A. Poland, MD, MEd, DFASAM: No financial relationships to disclose

Li Li, MD, PhD: No financial relationships to disclose

Madison Walsh, MS: No financial relationships to disclose

Updates on HCV Elimination in the US Developed in Collaboration with American Association for the Study of Liver Diseases

Friday, April 24, 2026

3:15 PM - 4:30 PM PT

Location: Regatta, Level 4

Presenter(s)

Ponni Perumalswami, MD

AASLD HCV SIG Chair

AASLD

Ann Arbor, Michigan

- CW

Carolyn Wester, MD, MPH

Director, Division of Viral Hepatitis

CDC

Atlanta, Georgia

Pauli Gray

Clinical Research Coordinator

USCF DeLIVER Care

San Francisco , California

- OF

Oluwaseun Falade-Nwulia, MBBS, MPH

Associate Professor
Johns Hopkins School of Medicine
Baltimore, Maryland

Despite significant progress in hepatitis C virus (HCV) treatment, new infections continue to outpace cures, with more than 2.4 million people still living with HCV in the U.S. This 90-minute symposium explores the latest data, evolving guidelines, and innovative strategies driving the nation toward HCV elimination. Join leading experts to examine how advances in diagnostics, simplified treatment, and patient-centered care are shaping the next chapter of HCV eradication in 2026.

Learning Objectives:

Learners will be able to:

- Review the most up to date epidemiology and diagnostics for hepatitis C virus (HCV) testing
- Explain simplified HCV treatment and updates to the guidelines
- Characterize the patient perspective of barriers to treatment in care settings

Disclosure(s):

Ponni Perumalswami, MD: No financial relationships to disclose

Pauli Gray: No financial relationships to disclose

Oluwaseun Falade-Nwulia, MBBS, MPH: No disclosure to display

General Session – Understanding the Evolving Drug Landscape: From Epidemiology to Clinical Practice

Friday, April 24, 2026

4:45 PM - 6:00 PM PT

Location: Seaport Ballroom, Level 2

Presenter(s)

- TG

Traci C. Green, PhD, MSc

Professor
Brandeis University, Heller School for Social Policy and Management
The Warren Alpert School of Medicine of Brown University
Brown University School of Public Health

Brandeis University/Brown University
Wayland, Massachusetts

Joseph D'Orazio, MD, FAAEM, FACMT, FASAM, FCPP

Associate Professor of Emergency Medicine
Cooper Medical School of Rowan University
Philadelphia, Pennsylvania

Kirsten E. Smith, PhD, LMSW

Consultant
Dial Square LLC
Baltimore, Maryland

Moderator(s)

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM

Director of Addiction Medicine
University of Rochester Medical Center
University of Rochester School of Medicine & Dentistry
Rochester, New York

Disclosure(s):

Traci C. Green, PhD, MSc: No financial relationships to disclose

Joseph D'Orazio, MD, FAAEM, FACMT, FASAM, FCPP: No financial relationships to disclose

Kirsten E. Smith, PhD, LMSW: No disclosure to display

Policy & Science General Session – Medicaid Matters: Policy Changes and Implications for Practice

Saturday, April 25, 2026

8:30 AM - 9:45 AM PT

Location: Seaport Ballroom, Level 2

Presenter(s)

- YO

Yngvild Olsen, MD, MPH, DFASAM

National Advisor
Manatt Health Services
Baltimore, Maryland

Regina LaBelle, JD

Professor, Director
Georgetown University
Washington, District of Columbia

Katie Greene, MPP

Director, Population and Public Health
National Academy for State Health Policy (NASHP)
Washington , District of Columbia

Moderator(s)

Stephen M. Taylor, MD, MPH, DFAPA, DFASAM

Chief Medical Officer
Pathway Healthcare Services, LLC
Jonesboro, Georgia

Disclosure(s):

Yngvild Olsen, MD, MPH, DFASAM: No financial relationships to disclose

Regina LaBelle, JD: No disclosure to display

Katie Greene, MPP: No financial relationships to disclose

Stephen M. Taylor, MD, MPH, DFAPA, DFASAM: No financial relationships to disclose

Addiction Medicine and the Law: Navigating Common Problems in Practice

Saturday, April 25, 2026

10:45 AM - 12:00 PM PT

Location: Harbor G-I, Level 2

Presenter(s)

Michael F. Weaver, MD, DFASAM

Professor & Medical Director
University of Texas Health Science Center at Houston
The University of Texas Health Science Center at Houston
Houston, Texas

Kelly J. Clark, MD, MBA, DFAPA, DFASAM

Founder
Addiction Crisis Solutions
Louisville, Kentucky

Margaret Jarvis, MD, DFASAM

Chief, Education
Geisinger Health System
Tunkhannock, Pennsylvania

Healthcare practitioners commonly encounter many legal and regulatory issues in Addiction Medicine practice. The panel members have expertise in navigating these common issues and will go over several cases to demonstrate ways to successfully navigate legal and regulatory aspects of Addiction Medicine practice. Cases will include: confidentiality, drug testing, impaired driving, medical necessity, disability, and more. Audience participation will be solicited throughout this workshop with smartphone-facilitated polling questions.

Learning Objectives:

Learners will be able to:

- Discuss legal issues in Addiction Medicine practice, including impact on professionals and patients, as well as the healthcare system.
- Recognize different settings where awareness of legal requirements are essential for a practicing Addiction Medicine professional.
- Implement improved medico-legal risk management processes in Addiction Medicine practice.

Disclosure(s):

Michael F. Weaver, MD, DFASAM: No financial relationships to disclose

Kelly J. Clark, MD, MBA, DFAPA, DFASAM: No disclosure to display

Margaret Jarvis, MD, DFASAM: No financial relationships to disclose

Bridging the Gap between Science and Clinical Practice

Developed in Collaboration with the National Institutes of Health and the Food and Drug Administration

Saturday, April 25, 2026

10:45 AM - 12:00 PM PT

Location: Regatta, Level 4

Presenter(s)

Wilson M. Compton, MD, MPE

Deputy Director
National Institute on Drug Abuse, Maryland

Geetha A. Subramaniam, MD, DLFAPA, DFAACAP

Deputy Director
NIDA
North Bethesda, Maryland

- GK

George F. Koob, PhD

Director
NIAAA
Bethesda, Maryland

Marta Sokolowska, PhD

Deputy Center Director for Substance Use and Behavioral Health
Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration
Laurel, Maryland

Ken I. Freedman, MD, MS, MBA, DFASAM, FACP, AGAF

Senior Medical Director
Aetna / CVS Health
Plantation, Florida

- TM

Tami L. Mark, PhD

Distinguished Fellow
RTI International
Bethesda, Maryland

The “Bridging the Gap” focus session is for addiction medicine clinical specialists, researchers, and federal research funding agencies (NIAAA, NIDA, FDA, and AHRQ) to discuss emerging trends and ways to improve alignment between research and clinical practice needs. Clinical specialists’ input on urgent clinical practice priorities will help guide research agencies in their efforts to make funding initiatives more responsive to everyday practice. The session will also provide updates on addiction research funding initiatives and promote collaborative research-practice partnerships.

Learning Objectives:

Learners will be able to:

- Upon completion, participants will be able to list at least three current areas of scientific focus from participating federal agencies.
- Upon completion, participants will be able to describe at least three emergent areas within addiction medicine that clinical specialists recommend for future scientific funding initiatives.
- Upon completion, participants will be able to explain the importance of bidirectional communication between science and clinical practice communities, and its potential to improve quality of care and promote health equity.

Disclosure(s):

Wilson M. Compton, MD, MPE: No disclosure to display

Geetha A. Subramaniam, MD, DLFAPA, DFAACAP: No financial relationships to disclose

George F. Koob, PhD: No financial relationships to disclose

Marta Sokolowska, PhD: No financial relationships to disclose

Ken I. Freedman, MD, MS, MBA, DFASAM, FACP, AGAF: No disclosure to display

Tami L. Mark, PhD: No financial relationships to disclose

Enhancing Access with Direct to Inject Buprenorphine: Evidence and Implementation

Saturday, April 25, 2026

10:45 AM - 12:00 PM PT

Location: Harbor D-F, Level 2

Presenter(s)

- JL

Josh Luftig, PA-C

Clinical Director & Co-Founder
The Bridge Center at The Public Health Institute
Point Reyes Station, California

Arianna D. Campbell, DMSc, MPH, PA-C, CAQ-EM, DFAAPA

Senior Director, M-PI
The Bridge Center at The Public Health Institute
Placerville, California

- AH

Andrew A. Herring, MD

Chief of Addiction Medicine
Alameda Health System
Oakland, California

Explore the latest evidence and practical implementation strategies for Direct-to-Inject extended-release buprenorphine, an innovative approach that eliminates traditional barriers to treatment initiation. This presentation synthesizes emerging research from emergency departments, inpatient settings, community clinics, and street medicine while providing actionable guidance for clinicians seeking to expand access to medications for opioid use disorder in their practice environments. Attendees will gain concrete knowledge to inform program development and clinical decision-making.

Learning Objectives:

Learners will be able to:

- (Comprehension Level) ...participants will be able to describe the current evidence supporting Direct-to-Inject extended-release buprenorphine including safety profile, patient outcomes, and treatment retention data.
- (Application Level) ...will be able to compare implementation models for DTI buprenorphine across diverse healthcare settings including emergency departments, inpatient units, community clinics, and street medicine programs.

- (Synthesis Level) Upon completion, participants will be able to formulate an implementation approach for DTI buprenorphine appropriate to their specific practice setting and patient population.

Disclosure(s):

Josh Luftig, PA-C: No financial relationships to disclose

Arianna D. Campbell, DMSc, MPH, PA-C, CAQ-EM, DFAAPA: No financial relationships to disclose

Expanding Telehealth to Optimize Buprenorphine Access and Mitigate Rural Treatment Barriers

Saturday, April 25, 2026

10:45 AM - 12:00 PM PT

Location: Coronado DE, Level 4

Presenter(s)

- JP

Jeanmarie Perrone, MD

Director, Center for Addiction Medicine and Policy
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Michael J. Lynch, MD FACEP FACMT

Associate Professor, Senior Medical Director
UPMC and UPMC Health Plan
Pittsburgh, Pennsylvania

- NG

Nicole M. Gastala, MD, MS

Chief of Integrated Behavioral Health and Addiction
UI Health Mile Square Health Center - University of Illinois Chicago
Chicago, Illinois

Non-presenting author(s)

- NO

Nicole O'Donnell, BA. CRS

Certified Recovery Specialist Director
University of Pennsylvania
Philadelphia, Pennsylvania

Eric Weintraub, MD

MD
University of Maryland
Towson, Maryland

Margaret Lowenstein, MD

Assistant Professor
University of Pennsylvania
Philadelphia, Pennsylvania

Gilly Gehri, MBE

Project Manager
University of Pennsylvania
Philadelphia, Pennsylvania

Explore how innovative telehealth models are expanding access to buprenorphine treatment and reducing barriers for rural and underserved populations. This interactive session features a panel of clinicians, navigators, and program leaders sharing real-world strategies, lessons learned, and implementation tools to improve equity and retention in medications for opioid use disorder (MOUD) care. Breakout discussions will help participants tailor solutions to their own settings and populations.

Learning Objectives:

Learners will be able to:

- Describe telehealth models expanding MOUD access in rural, regional, and urban settings to identify effective and sustainable practices.
- Evaluate strategies for initiating and retaining patients on buprenorphine via telehealth, with emphasis on improving continuity of care in rural and underserved communities.
- Design an action plan to implement equitable, patient-centered telehealth approaches that address barriers unique to rural populations.

Disclosure(s):

Jeanmarie Perrone, MD: No financial relationships to disclose

Michael J. Lynch, MD FACMT: No financial relationships to disclose

Nicole M. Gastala, MD, MS: No financial relationships to disclose

Nicole O'Donnell, BA. CRS: No financial relationships to disclose

Eric Weintraub, MD: No financial relationships to disclose

Margaret Lowenstein, MD: No financial relationships to disclose

Gilly Gehri, MBE: No financial relationships to disclose

Expanding Telehealth to Optimize Buprenorphine Access and Mitigate Rural Treatment Barriers

Saturday, April 25, 2026

10:45 AM - 12:00 PM PT

Location: Coronado DE, Level 4

Presenter(s)

- JP

Jeanmarie Perrone, MD

Director, Center for Addiction Medicine and Policy
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Michael J. Lynch, MD FACEP FACMT

Associate Professor, Senior Medical Director
UPMC and UPMC Health Plan
Pittsburgh, Pennsylvania

- NG

Nicole M. Gastala, MD, MS

Chief of Integrated Behavioral Health and Addiction
UI Health Mile Square Health Center - University of Illinois Chicago
Chicago, Illinois

Non-presenting author(s)

- NO

Nicole O'Donnell, BA. CRS

Certified Recovery Specialist Director
University of Pennsylvania
Philadelphia, Pennsylvania

Eric Weintraub, MD

MD
University of Maryland
Towson, Maryland

Margaret Lowenstein, MD

Assistant Professor
University of Pennsylvania
Philadelphia, Pennsylvania

Gilly Gehri, MBE

Project Manager
University of Pennsylvania
Philadelphia, Pennsylvania

Explore how innovative telehealth models are expanding access to buprenorphine treatment and reducing barriers for rural and underserved populations. This interactive session features a panel of clinicians, navigators, and program leaders sharing real-world strategies, lessons learned, and implementation tools to improve equity and retention in medications for opioid use disorder (MOUD) care. Breakout discussions will help participants tailor solutions to their own settings and populations.

Learning Objectives:

Learners will be able to:

- Describe telehealth models expanding MOUD access in rural, regional, and urban settings to identify effective and sustainable practices.
- Evaluate strategies for initiating and retaining patients on buprenorphine via telehealth, with emphasis on improving continuity of care in rural and underserved communities.
- Design an action plan to implement equitable, patient-centered telehealth approaches that address barriers unique to rural populations.

Disclosure(s):

Jeanmarie Perrone, MD: No financial relationships to disclose

Michael J. Lynch, MD FACMT: No financial relationships to disclose

Nicole M. Gastala, MD, MS: No financial relationships to disclose

Nicole O'Donnell, BA. CRS: No financial relationships to disclose

Eric Weintraub, MD: No financial relationships to disclose

Margaret Lowenstein, MD: No financial relationships to disclose

Gilly Gehri, MBE: No financial relationships to disclose

Finding Connection: Addressing Loneliness in People Living with Substance Use Disorder

Saturday, April 25, 2026

10:45 AM - 12:00 PM PT

Location: Coronado A-C, Level 4

Presenter(s)**Devin Oller, MD**

Associate Professor of Medicine
UCSF Division of General Internal Medicine
San Francisco, California

- IK

Irina (Era) V. Kryzhanovskaya, MD

Associate Professor of Medicine
UCSF
San Francisco, California

Sienna Kurland, MD, MPH

Assistant Professor of Medicine
UCSF
San Francisco, California

Non-presenting author(s)

- JR

Jessica Ristau, MD

Dr.
UCSF
San Francisco, California

We know the opposite of addiction is connection, but addressing the crisis of loneliness in SUD-focused care settings can feel overwhelming—How do you even start the conversation? This workshop seeks to review evidence-based strategies for screening and managing loneliness, and to empower clinicians with practical skills to better help their clients with SUD find connection.

Learning Objectives:

Learners will be able to:

- Identify common risk factors and validated screening tools for patients experiencing loneliness.
- Demonstrate a brief intervention for loneliness, and describe barriers and facilitators to implementing this intervention in one's own practice
- Recognize strategies for institutional and community-based advocacy to improve the resources available to patients experiencing loneliness

Disclosure(s):

Devin Oller, MD: No financial relationships to disclose

Irina (Era) V. Kryzhanovskaya, MD: No financial relationships to disclose

Sienna Kurland, MD, MPH: No disclosure to display

Jessica Ristau, MD: No financial relationships to disclose

High Risk at Every Stage: Cannabis Exposure During Critical Periods of Development

Saturday, April 25, 2026

10:45 AM - 12:00 PM PT

Location: Gaslamp, Level 2

Presenter(s)

Sukhmeet Sandhu, MD

Addiction Medicine Physician
Children's Hospital Colorado / University of Colorado School of Medicine
Denver, Colorado

[Danae Massengill, MD](#)

Medical Toxicologist and Assistant Professor of Pediatrics
Children's Hospital Colorado, University of Colorado School of Medicine
Denver, Colorado

[Laurie S. Halmo, MD, FAAP](#)

Medical Toxicologist and Associate Professor of Pediatrics
University of Colorado School of Medicine
Denver, Colorado

Cannabis exposure during pregnancy, childhood and adolescence can have lasting effects on health and development. This session will explore the effects of cannabis exposure during these critical developmental periods. Participants will also learn to apply evidence-based strategies for prevention, counseling, and harm reduction.

Learning Objectives:

Learners will be able to:

- Describe the effects of cannabis exposure during the perinatal, childhood, and adolescent developmental periods.
- Recognize short and long-term health outcomes associated with cannabis exposure during the perinatal, childhood, and adolescent developmental periods, including the neurodevelopmental, behavioral, and physical effects of THC.
- Apply strategies learned from the session to aid in prevention, counseling/discussion, and harm reduction education around cannabis use for youth and families

Disclosure(s):

Sukhmeet Sandhu, MD: No financial relationships to disclose

Danae Massengill, MD: No financial relationships to disclose

Laurie S. Halmo, MD, FAAP: No financial relationships to disclose

Improving Engagement and Retention in Opioid Treatment through Measurement-Based Care

Saturday, April 25, 2026

10:45 AM - 12:00 PM PT

Location: Balboa, Level 2

Presenter(s)

[Renee M. Cloutier, PhD](#)

Assistant Professor
HEALing Measures Center; Center for Research on Health Care
Pittsburgh, Pennsylvania

[Robert Ryan, LPC, NCC, PMP](#)

Program Manager/Lead Implementation Specialist
University of Pittsburgh
Pittsburgh, Pennsylvania

Non-presenting author(s)

[Ani Lessley, BA](#)

Research Study Assistant
Northwestern University Feinberg School of Medicine
Chicago, Illinois

[Kelli Scott, PhD](#)

Assistant Professor
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Recent policy shifts, including SAMHSA's revised 42 CFR Part 8 Final Rule, highlight the need for patient-centered, flexible, and evidence-informed practices in opioid treatment programs (OTPs). This interactive Focus Session introduces measurement-based care (MBC)—an evidence-based approach that uses patient-reported outcomes to enhance patient engagement, retention, and quality of care. Participants will learn how to implement MBC within OTP workflows to meet evolving policy, accreditation, and payer expectations while reducing documentation burden and improving treatment outcomes.

Learning Objectives:

Learners will be able to:

- 1. Describe the core components and evidence base of measurement-based care (MBC).

- 2. Explain how MBC supports patient engagement, retention, and shared decision-making.
- 4. Recognize common barriers and facilitators to MBC adoption and sustainability.

Disclosure(s):

Renee M. Cloutier, PhD: No financial relationships to disclose

Robert Ryan, LPC, NCC, PMP: No financial relationships to disclose

Ani Lessley, BA: No financial relationships to disclose

Kelli Scott, PhD: No financial relationships to disclose

Promoting Integrated Care Throughout the SUD and Mental Health Treatment Systems

Saturday, April 25, 2026

10:45 AM - 12:00 PM PT

Location: Harbor A-C, Level 2

Presenter(s)

R. Corey Waller, MD, MS, FACEP, DFASAM

Executive Advisor in Behavioral Health
Shore Capital Partners
Ann Arbor, Michigan

Lisa R. Fortuna, MD, MPH

PROFESSOR AND CHAIR
University of California Riverside
Riverside, California

Anish Dhamija, MD

Director of Behavioral Health
Imperial Beach Community Clinic
Poway, California

Brian Hurley, MD, M.B.A., FAPA, DFASAM

Medical Director
Los Angeles County Department of Public Health
Los Angeles, California

Utilization of uniform national standards for service intensity assessment and planning for mental health (MH) and substance use disorder (SUD) care supports equitable access to the full continuum of MH and SUD care at the patient level and facilitates benchmarking of service utilization at the system/community level.

Learning Objectives:

Learners will be able to:

- Examine the role of level of care determination standards play in supporting access to clinically appropriate types and intensities of services that best address an individual's behavioral health needs.
- Explore how standardized clinical decision-support tools support objective, unbiased, and equitable service planning recommendations.
- Critically evaluate how service intensity and level of care standards can support improved resource allocation and drive iterative quality improvement.

Disclosure(s):

R. Corey Waller, MD, MS, FACEP, DFASAM: No financial relationships to disclose

Lisa R. Fortuna, MD, MPH: No financial relationships to disclose

Anish Dhamija, MD: No financial relationships to disclose

The Right Dose, Every Day

Saturday, April 25, 2026

10:45 AM - 12:00 PM PT

Location: America's Cup, Level 4

Presenter(s)

- RP

Ruth A. Potee, MD DFASAM

Medical Director
Behavioral Health Network
Northfield, Massachusetts

Ari Kriegsman, MD FASAM

Medical Director BHN Springfield OTP, Carlson Recovery Center
Behavioral Health Network
Florence, Massachusetts

Daniel Liauw, MD MPH FASAM

Primary Care and Addiction Physician
Massachusetts General Hospital/Harvard Medical School
Boston, Massachusetts

The most important thing about methadone is taking the right dose(s) every day. This session covers strategies to improve this, including split dosing, increasing take home bottles, safe and accelerated induction titrations, and non-punitive missed dose approaches. In addition, we will explore methods for transitioning patients from methadone to buprenorphine, including direct-to-inject buprenorphine.

Learning Objectives:

Learners will be able to:

- Apply evidence-based strategies to titrate methadone doses and manage missed doses [patient care]
- Identify common clinical presentations when split dosing and increased take home dosing of methadone could improve patient outcomes [patient care, systems-based practice]
- Counsel a patient in options for transitioning from methadone to buprenorphine [patient care, interpersonal communication skills]

Disclosure(s):

Ruth A. Potee, MD DFASAM: No financial relationships to disclose

Ari Kriegsman, MD FASAM: No financial relationships to disclose

Daniel Liauw, MD MPH FASAM: No financial relationships to disclose

When AUD Isn't the Only Diagnosis: Navigating Co-Occurring Psychiatric Conditions

Saturday, April 25, 2026

10:45 AM - 12:00 PM PT

Location: Seaport Ballroom, Level 2

Presenter(s)

Smita Das, MD, PhD, MPH

Clinical Associate Professor
Stanford University
Cupertino, California

Stephanie A. Vail, PharmD, MPH, BCPP, FCCP, FAAPP

Professor of Pharmacy Practice
University of New England
Saco, Maine

Managing alcohol use disorder (AUD) in patients with co-occurring psychiatric conditions, such as depression, anxiety, bipolar disorder, and PTSD, is common and clinically complex. This session uses a patient case to bridge theory and practice, equipping addiction medicine clinicians with practical strategies for effective care. Participants will gain tools to navigate screening and diagnostic challenges, develop treatment plans that combine pharmacologic and behavioral approaches, and overcome common clinical barriers to improve outcomes for individuals with co-occurring AUD and psychiatric disorders.

Learning Objectives:

Learners will be able to:

- Apply validated screening and diagnostic tools to identify co-occurring psychiatric conditions in patients presenting with AUD.
- Develop integrated and interdisciplinary treatment plans that address both AUD and co-occurring psychiatric conditions using evidence-based pharmacologic and behavioral interventions.
- Assess common barriers to care for patients with co-occurring disorders and implement strategies to improve treatment engagement and outcomes.

Disclosure(s):

Smita Das, MD, PhD, MPH: No financial relationships to disclose

Stephanie D. Vail, PharmD, MPH, BCPP, FCCP, FAAPP: No financial relationships to disclose

Beyond Screening: Implementing a Response to Substance Use Coercion in Clinical Practice

Saturday, April 25, 2026

1:30 PM - 2:45 PM PT

Location: Gaslamp, Level 2

Presenter(s)

- IH

Ilana Hull, MD, MSc

Assistant Professor of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Diana Samberg, MD, MS

Assistant Professor
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Carole Warshaw, MD

Director
National Center on Domestic Violence, Trauma, and Mental Health
Chicago, Illinois

Non-presenting author(s)

Heather Phillips, MA

Research Director
National Center on Domestic Violence, Trauma, and Mental Health
Jackson Heights, New York

Lauren T. Narbey, CNM, PhD

Assistant Professor
Duquesne University
Pittsburgh, Pennsylvania

This focus session will teach about substance use coercion, a form intimate partner violence (IPV) where an abusive partner uses substances as a means of control. We will present new updates to toolkit, informed by a pilot intervention study, that can be used by clinics aiming to created an integrated, multidisciplinary approach to substance use coercion in their clinical settings.

Learning Objectives:

Learners will be able to:

- Describe the key tactics used in substance use coercion within intimate partner violence (IPV) relationships and their impact on recovery and treatment.
- Identify key components of a comprehensive approach for identifying and addressing substance use coercion in clinical settings
- Utilize resources that can help support individuals experiencing SUC and providers aiming to support these patients

Disclosure(s):

Ilana Hull, MD, MSc: No financial relationships to disclose

Diana Samberg, MD, MS: No financial relationships to disclose

Carole Warshaw, MD: No financial relationships to disclose

Heather Phillips, MA: No financial relationships to disclose

Lauren T. Narbey, CNM, PhD: No financial relationships to disclose

Beyond Screening: Implementing a Response to Substance Use Coercion in Clinical Practice

Saturday, April 25, 2026

1:30 PM - 2:45 PM PT

Location: Gaslamp, Level 2

Presenter(s)

- IH

[Ilana Hull, MD, MSc](#)

Assistant Professor of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

[Diana Samberg, MD, MS](#)

Assistant Professor
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Carole Warshaw, MD

Director
National Center on Domestic Violence, Trauma, and Mental Health
Chicago, Illinois

Non-presenting author(s)

Heather Phillips, MA

Research Director
National Center on Domestic Violence, Trauma, and Mental Health
Jackson Heights, New York

Lauren T. Narbey, CNM, PhD

Assistant Professor
Duquesne University
Pittsburgh, Pennsylvania

This focus session will teach about substance use coercion, a form intimate partner violence (IPV) where an abusive partner uses substances as a means of control. We will present new updates to toolkit, informed by a pilot intervention study, that can be used by clinics aiming to create an integrated, multidisciplinary approach to substance use coercion in their clinical settings.

Learning Objectives:

Learners will be able to:

- Describe the key tactics used in substance use coercion within intimate partner violence (IPV) relationships and their impact on recovery and treatment.
- Identify key components of a comprehensive approach for identifying and addressing substance use coercion in clinical settings
- Utilize resources that can help support individuals experiencing SUC and providers aiming to support these patients

Disclosure(s):

Ilana Hull, MD, MSc: No financial relationships to disclose

Diana Samberg, MD, MS: No financial relationships to disclose

Carole Warshaw, MD: No financial relationships to disclose

Heather Phillips, MA: No financial relationships to disclose

Lauren T. Narbey, CNM, PhD: No financial relationships to disclose

Bridging Gaps: Clinical and Ethical Challenges for Patients with Addiction and Cancer

Saturday, April 25, 2026

1:30 PM - 2:45 PM PT

Location: America's Cup, Level 4

Presenter(s)

Janet J. Ho, MD MPH

Associate Professor
University of California, San Francisco
san francisco, California

Katrina S. Nickels, MD, DFASAM

Assistant Professor
University of Kentucky College of Medicine
Lexington, Kentucky

A. Justine Landi, MD, MPH

Associate Professor
University of Louisville
Louisville, Kentucky

Julie W. Childers, MD, FASAM

Professor of Medicine
University of Pittsburgh
Pittsburgh, Pennsylvania

Participants in this interactive session will explore cases at the challenging intersection of addiction, pain, and cancer. Clinicians boarded in addiction and palliative medicine guide participants through clinical tools and scenarios that: prioritize options for managing concurrent addiction and cancer pain, approach a differential and treatment options for chronic cancer pain and prescription OUD versus OUD, and consider ethical responsibilities in addiction and cancer treatment when patient autonomy conflicts with clinical care in the 'best interest' of the patient.

Learning Objectives:

Learners will be able to:

- 1. Apply a multi-dimensional assessment/ 4P framework to help prioritize more appropriate and safer opioid options in patients with pain, cancer, and addiction
- 2. Compare features and management approaches for chronic cancer pain and OUD or prescription OUD or Complex persistent opioid dependence
- 3. Examine ethical and clinical considerations when patients with untreated OUD and cancer decline medications for OUD, cancer treatment, and resuscitation

Disclosure(s):

Janet J. Ho, MD MPH: No financial relationships to disclose

Katrina S. Nickels, MD, DFASAM: No financial relationships to disclose

A. Justine Landi, MD, MPH: No financial relationships to disclose

Julie W. Childers, MD, FASAM: No financial relationships to disclose

Envisioning a Continuum of Care for Behavioral Addictions

Saturday, April 25, 2026

1:30 PM - 2:45 PM PT

Location: Harbor D-F, Level 2

Presenter(s)

Sara J. Polley, MD, FAPA, FASAM

Child, Adolescent, Adult, Addiction Psychiatrist
Vantage Mental Health
Minneapolis, Minnesota

Michael Eiden, PhD, LCSW, LCADC, CSAT, CCS

Therapist
Eiden Integrative Counseling
Milwaukie, Oregon

Daniel Kaufmann, PhD, LPC, LMHC

Director of Gaming Services & Program Development | Associate Professor
Kindbridge Behavioral Health | Grand Canyon University
Orlando, Florida

Margaret Jarvis, MD, DFASAM

Chief, Education
Geisinger Health System
Tunkhannock, Pennsylvania

Non-presenting author(s)

Emily Brunner, MD

Supervising physician consultant
Hazelden Betty Ford Foundation
Lake Elmo, Minnesota

Explore the first-ever integration of behavioral addictions into the ASAM Criteria and the challenges the editorial team has faced in defining, assessing, and treating these conditions. This session combines expert insights, panel discussion, and audience Q&A to give attendees a behind-the-scenes look at this groundbreaking work and practical takeaways for clinical practice.

Learning Objectives:

Learners will be able to:

- Describe the scope and rationale for including behavioral addictions in the ASAM Criteria, highlighting the challenges and considerations in defining, assessing, and treating these conditions.
- Explain key components of the ongoing development process for the Behavioral Addictions Volume and how multidimensional assessment is applied to non-substance addictions.
- Apply insights from the editorial process to clinical practice by identifying strategies for integrating assessment and treatment of behavioral addictions into everyday addiction care.

Disclosure(s):

Sara J. Polley, MD, FAPA, FASAM: No financial relationships to disclose

Michael Eiden, PhD, LCSW, LCADC, CSAT, CCS: No financial relationships to disclose

Daniel Kaufmann, PhD, LPC, LMHC: No financial relationships to disclose

Emily Brunner, MD: No financial relationships to disclose

Expanding Your "Us": Strengthening Police & SUD Provider Partnerships to Build RESILIENCE

Saturday, April 25, 2026

1:30 PM - 2:45 PM PT

Location: Coronado DE, Level 4

Presenter(s)

Jennifer L. Holm, MSW, MA-TASL, LMSW, BEI I

Police Social Worker Coordinator
Traverse City Police Department
Traverse City, Michigan

Paula Lipinski, MSW,

Chief Executive Officer
Addiction Treatment Services
Traverse City, Michigan

Limited collaboration across systems, including justice, physical and mental health, and housing, creates barriers for treating individuals with SUD. To address actionable strategies to overcome these obstacles, Addiction Treatment Services and the Traverse City Police Department (TCPD) will discuss the establishment of their robust partnership and the development of the TCPD RESILIENCE Program. This interactive workshop will then challenge audience members to tackle a collaboration barrier, whether with law enforcement or another crucial service system, in their own practice settings.

Learning Objectives:

Learners will be able to:

- ...critique ways in which their current practices further separates “us” vs. “them.”
- ...analyze sectors of greatest divide in their communities and for their clients, and calculate the imminence and magnitude of such system separation
- ...formulate a needed partnership discussion in their communities.

Disclosure(s):

Jennifer L. Holm, MSW, MA-TASL, LMSW, BEI I: No financial relationships to disclose

Paula Lipinski, MSW,: No financial relationships to disclose

Incorporating Artificial Intelligence into your Research Workflow: A Hands-On Workshop

Saturday, April 25, 2026

1:30 PM - 2:45 PM PT

Location: Coronado A-C, Level 4

Presenter(s)

[Cara Borelli, DO](#)

Assistant professor
Yale School of Medicine
New Haven, Connecticut

[Alyssa Cheng, DO](#)

Addiction Medicine Fellow
Yale University
New Haven, Connecticut

[Molly MacInnes Perri, MD](#)

Assistant Professor
University of Illinois College of Medicine Rockford
Inverness, Illinois

[Lilian Denzler](#)

PhD Student
Yale, UCL
New Haven, Connecticut

This workshop will provide attendees with a basic understanding of the benefits and limitations of artificial intelligence (AI) in research. The workshop will include didactics, live demonstrations of AI, and a hands-on component. Attendees will gain skills to incorporate AI into their research workflow, including using AI to assist with literature reviews, develop grant outlines, and provide mock peer review, and discuss other innovative ways to incorporate AI into research in addiction medicine.

Learning Objectives:

Learners will be able to:

- Describe the limitations and risks of using artificial intelligence in addiction research
- Construct optimized search queries with iterative improvements
- Incorporate basic skills in using artificial intelligence to improve research in addiction medicine

Disclosure(s):

Cara Borelli, DO: No disclosure to display

Alyssa Cheng, DO: No financial relationships to disclose

Molly MacInnes Perri, MD: No financial relationships to disclose

Lilian Denzler: No financial relationships to disclose

The Short-Term Impacts of Drug Decriminalization in British Columbia

Saturday, April 25, 2026

1:30 PM - 2:45 PM PT

Location: Balboa, Level 2

Presenter(s)

- CR

Cayley Russell, MA

Research Manager
Centre for Addiction and Mental Health
Toronto, Ontario

Sameer Imtiaz, PhD

Staff Scientist
Center for Addiction and Mental Health
Toronto, Ontario

Juls Budau, MSW

Research Advisor
UBC School of Population & Public Health
Victoria, BC, British Columbia

This session explores the short-term impacts of British Columbia, Canada's, landmark drug decriminalization policy through an integrated presentation of quantitative, qualitative, and mixed-method findings. Presenters will share insights from people who use drugs, police officers, and health service providers, examining shifts in overdose trends, service delivery, and criminal justice outcomes. Featuring diverse perspectives—including lived experience—the session will highlight lessons learned, persistent inequities, and implications for shaping equitable drug policy reform in Canada and beyond.

Learning Objectives:

Learners will be able to:

- Describe key short-term impacts of British Columbia's drug decriminalization and re-criminalization policies on overdose deaths, service utilization, and criminal justice outcomes.
- Explain how decriminalization and its partial repeal have influenced the experiences of people who use drugs, policing practices, and the operations of harm reduction and treatment services across BC.
- Discuss the policy and practice implications of BC's experience to inform evidence-based, equitable, and health-focused approaches to future drug policy reforms.

Disclosure(s):

Cayley Russell, MA: No financial relationships to disclose

Sameer Imtiaz, PhD: No financial relationships to disclose

Juls Budau, MSW: No financial relationships to disclose

Treatment of Alcohol Use Disorder in Patients with Liver Disease

Saturday, April 25, 2026

1:30 PM - 2:45 PM PT

Location: Harbor A-C, Level 2

Presenter(s)

- DA

[Divya Ayyala-somayajula, MD MAS](#)

Assistant Professor of Medicine
Thomas Jefferson University
PHILADELPHIA, Pennsylvania

Thomas Bottyan, MD

Addiction Psychiatrist
VA Northern California
Mather, California

- ST

Steven Tate, MD, MSc, FASAM, FACP

Clinical Assistant Professor
Stanford University School of Medicine
San Francisco, California

Deirdra Kelly, MD

Psychiatry Resident
University of California Davis
Sacramento, California

Non-presenting author(s)

Gargi Bhattacharya, MD

Fellow, Addiction Medicine
Stanford University School of Medicine
Stanford, California

This session provides practical, evidence-based guidance for treating Alcohol Use Disorder (AUD) in patients with liver disease across inpatient, outpatient, and transplant settings. Participants will gain tools to navigate treatment decisions, improve clinical outcomes, and support equitable care.

Learning Objectives:

Learners will be able to:

- 1. Evaluate the evidence and safety data for FDA-approved and off-label AUD pharmacotherapies in patients with liver disease, identifying indications and contraindications.
- 2. Develop safe and effective, evidence-based treatment plans for AUD in patients pre- and post-liver transplant.
- 3. Integrate psychosocial, mutual-support, and integrated care models into the management of AUD for patients with hepatic dysfunction.

Disclosure(s):

Divya Ayyala-somayajula, MD MAS: No financial relationships to disclose

Thomas Bottyan, MD: No financial relationships to disclose

Steven Tate, MD, MSc, FASAM, FACP: No financial relationships to disclose

TV 101: Mastering Media Skills to Pitch and Promote Addiction Treatment

Saturday, April 25, 2026

1:30 PM - 2:45 PM PT

Location: Harbor G-I, Level 2

Presenter(s)

[Lee Radosh, MD, FAAFP, FASAM](#)

Section Chief

Reading Hospital and Tower Health Medical Group

Sinking Spring, Pennsylvania

[Jodi Radosh, PhD](#)

Professor

Alvernia University

Sinking Spring, Pennsylvania

Addiction medicine clinicians can expand their impact by confidently engaging with the media to promote awareness and evidence-based care. Through concise instruction and hands-on practice, this dynamic session equips providers to identify newsworthy stories within their practices, connect with the media, address addiction in pop culture, and deliver treatment messages on camera with clarity, confidence, and clinical credibility.

Learning Objectives:

Learners will be able to:

- Identify newsworthy stories or initiatives within their clinical practice that could engage the media and promote addiction treatment.
- Describe effective strategies for contacting journalists, pitching stories, and tailoring messages across traditional and social media platforms.

- Demonstrate how to prepare for a media interview, including what to expect, how to stay on message, and how to deliver key points clearly and confidently.

Disclosure(s):

Lee Radosh, MD, FAAFP, FASAM: No financial relationships to disclose

Jodi Radosh, PhD: No financial relationships to disclose

Withdrawal, Discontinuation Syndromes, or Nil for Atypical Substances of Misuse

Saturday, April 25, 2026

1:30 PM - 2:45 PM PT

Location: Seaport Ballroom, Level 2

Presenter(s)

Robert Cole Pueringer, MD

Addiction Medicine, Medical Toxicology; Medical Director of Substance Use and Addiction Care Program
Essentia Health
Duluth, Minnesota

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM

Director of Addiction Medicine
University of Rochester Medical Center
University of Rochester School of Medicine & Dentistry
Rochester, New York

JoAn Laes, MD

Addiction Physician
Allina
Minneapolis, Minnesota

Ashley Haynes, MD

Medical Toxicology, Addiction Medicine
University of Kansas, School of Medicine - Wichita
Andover, Kansas

Non-presenting author(s)

Sarah Usher, MD

Addiction Medicine Physician Fellow; Emergency Medicine Physician
University of Minnesota
Minneapolis, Minnesota

Evan S. Schwarz, MD, FASAM

Clinical Professor of Emergency Medicine, Medical Toxicology Fellowship Director
UCLA
Los Angeles, California

Patients increasingly present to the hospital and medical detoxification units with withdrawal syndromes from nontraditional or emerging substances. This case-based session delivers practical, protocol-ready guidance for risk stratification and withdrawal management of dextromethorphan, kratom, cannabis, ketamine, gamma-hydroxybutyrate (GHB), and phenibut. We review clinical phenotypes, risk stratification, and inpatient withdrawal management regimens (first-line and reasonable alternatives), including when to involve Addiction Medicine or Toxicology services and bridging therapy to outpatient care. We will emphasize where evidence is strong vs. provisional.

Learning Objectives:

Learners will be able to:

- Describe intoxication and withdrawal physiology and phenotypes for dextromethorphan, kratom, cannabinoids, ketamine, gamma-hydroxybutyrate (GHB), and phenibut.
- Compare evidence-informed pharmacologic and supportive strategies for acute withdrawal management, including established and emerging protocols.
- Describe risk stratification and practical order sets with monitoring tailored to medical detoxification unit resources.

Disclosure(s):

Robert Cole Pueringer, MD: No financial relationships to disclose

JoAn Laes, MD: No financial relationships to disclose

Ashley Haynes, MD: No financial relationships to disclose

Sarah Usher, MD: No financial relationships to disclose

Evan S. Schwarz, MD, FASAM: No financial relationships to disclose

Beyond Withdrawal: Optimizing Pain in the Opioid Tolerant Patient

Saturday, April 25, 2026

4:45 PM - 6:00 PM PT

Location: Harbor D-F, Level 2

Presenter(s)

Joseph D'Orazio, MD, FAAEM, FACMT, FASAM, FCPP

Associate Professor of Emergency Medicine
Cooper Medical School of Rowan University
Philadelphia, Pennsylvania

Christine Collins, MD

Assistant Professor of Emergency Medicine
Cooper University Hospital
Haddon Township, New Jersey

Non-presenting author(s)

Sam J. Stern, MD

Associate Professor of Clinical Medicine
Temple University Hospital
Philadelphia, Pennsylvania

This session equips addiction medicine clinicians with practical strategies to manage both pain and withdrawal in patients with severe opioid tolerance. Through a blend of didactic teaching and interactive case discussions, participants will explore basal-bolus opioid approaches, PCA use, the roles of methadone and buprenorphine, and multimodal non-opioid therapies. Attendees will leave with evidence-based, patient-centered tools to improve pain outcomes while reducing healthcare disparities.

Learning Objectives:

Learners will be able to:

- Upon completion, participants will be able to apply a basal-bolus approach to managing patients with severe opioid dependence and tolerance
- Upon completion, participants will learn how to use long and short-acting opioids, including methadone and buprenorphine, as well as PCA pump to manage both withdrawal and pain in the inpatient and perioperative settings

- Upon completion, participants will learn how to incorporate multimodal non-opioid therapies, including regional anesthesia, into individualized treatment plans to optimize analgesia and reduce disparities in care.

Disclosure(s):

Joseph D'Orazio, MD, FAAEM, FACMT, FASAM, FCPP: No financial relationships to disclose

Christine Collins, MD: No financial relationships to disclose

Ensuring Access to Medications for Opioid Use Disorder During Climate Disasters

Saturday, April 25, 2026

4:45 PM - 6:00 PM PT

Location: America's Cup, Level 4

Presenter(s)

- MS

Matthew Salzman, MD, MPH

Associate Professor
Cooper Medical School of Rowan University
Camden, New Jersey

Cordelia Stearns, MD, AAHIVS

Chief Medical Officer
High Country Community Health
Boone, North Carolina

- RH

Rachel Haroz, MD

Center Head, Cooper Center for Healing
Cooper University Health Care
Camden, New Jersey

Non-presenting author(s)

Elizabeth Cerceo, MD, DCM

Professor of Medicine
Cooper Medical School of Rowan University
Cherry Hill, New Jersey

This workshop is designed for addiction medicine specialists, primary care and emergency medicine clinicians, OTP staff, pharmacists, policymakers, health system administrators, and community-based providers interested in building disaster-resilient systems for OUD treatment.

Learning Objectives:

Learners will be able to:

- Upon completion, participant will be able to describe how climate disasters disrupt access to MOUD and the resulting risks for patients with OUD.
- Upon completion, participant will be able to identify regulatory, infrastructural, and equity-related barriers that impede MOUD continuity during emergencies.
- Upon completion, participant will be able to apply lessons learned from recent disasters to evaluate strategies for integrating MOUD into disaster preparedness plans

Disclosure(s):

Matthew Salzman, MD, MPH: No financial relationships to disclose

Elizabeth Cerceo, MD, DCM: No financial relationships to disclose

Cordelia Stearns, MD, AAHIVS: No financial relationships to disclose

Rachel Haroz, MD: No financial relationships to disclose

Hot Takes: Smoking Practices and Emerging Risks Amid Stimulants, Fentanyl, and Torches

Saturday, April 25, 2026

4:45 PM - 6:00 PM PT

Location: Harbor G-I, Level 2

Presenter(s)

Honora Englander, MD

Professor; Founding Director, Improving Addiction Care Team
Oregon Health & Science University
Portland, Oregon

Elizabeth M. Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM

Professor of Family Medicine and Community Health
University of Wisconsin, Madison School of Medicine and Public Health
Madison, Wisconsin

James Duffy

Founding Director
Smoke Works
Boston, Massachusetts

William H. Eger, PhD(c), MPH

PhD Candidate
UC San Diego
San Francisco, California

- AW

Alexander Y. Walley, MD, MSc, DFASAM

Professor of Medicine
Boston University Chobanian & Avedisian School of Medicine
Boston, Massachusetts

Michael Incze, MD, MEd

Associate Professor
University of Utah
Salt Lake City, Utah

Kayla Houston, BS

Alcohol and Other Drug Outreach Worker
Father Joe's Villages
San Diego, California

As smoking surpasses injection as the most common route of fatal overdose, clinicians and community providers should understand the emerging risks and harm reduction needs of people who smoke drugs. This interactive workshop explores evolving smoking practices, related health harms, and effective risk mitigation strategies. Participants will engage in hands-on demonstrations and discussions led by clinicians, researchers, and people with lived experience to inform safer smoking interventions and improve care across diverse settings.

Learning Objectives:

Learners will be able to:

- Describe current trends in drug smoking practices and associated health risks, including burns, pulmonary disease, and overdose.
- Demonstrate safe handling techniques for smoking devices (e.g. dabbers, pipes) and heat sources (e.g. torches), and apply communication strategies for engaging clients who smoke drugs.
- Identify evidence-based harm reduction interventions and opportunities to integrate safer smoking practices into clinical and community programs.

Disclosure(s):

Honora Englander, MD: No financial relationships to disclose

Elizabeth M. Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM: No financial relationships to disclose

James Duffy: No financial relationships to disclose

William H. Eger, PhD(c), MPH: No financial relationships to disclose

Kayla A.E Houston, Bachelors of Science: No financial relationships to disclose

Innovations in Addiction Medicine on the Street: SUD treatments for the Unhoused

Saturday, April 25, 2026

4:45 PM - 6:00 PM PT

Location: Balboa, Level 2

Presenter(s)

[Katia Cnop, DO](#)

Associate Medical Director / Associate Clinical Faculty of Family Medicine
USC Street Medicine / Keck School of Medicine
Sierra Madre, California

Camilo Zaks, MD, FAAFP

Medical Director/ Clinical Associate Professor
USC Street Medicine/ Keck School of Medicine of USC
Los Angeles, California

Shane Collins, MD, MS

Psychiatrist, Assistant Professor of Psychiatry and the Behavioral Sciences
University of Southern California
Redondo Beach, California

People experiencing unsheltered homelessness suffer a marked increase in morbidity and mortality compared to the general population, with overdose consistently cited as the leading cause of death. This universally applicable didactic and case study session offers innovative Street Medicine treatment strategies for Opioid Use Disorder and Stimulant Use Disorder, contextualized to meet the dynamic needs of people living outside. By the end of this session, participants will be equipped to utilize these strategies for patients seen across all clinical settings.

Learning Objectives:

Learners will be able to:

- appraise the homelessness crisis in the United States, Street Medicine as a solution, and the unique challenges those experiencing unsheltered homelessness face when attempting to access to SUD treatment.
- apply several Direct-To-Inject buprenorphine induction strategies, and describe how these strategies may be utilized to overcome barriers to OUD treatment experienced by those who are unsheltered.
- consider how psychostimulant medications and GLP-1RA may be utilized to treat Substance Use Disorders, and how these medications address unique considerations for unsheltered patients.

Disclosure(s):

Katia Cnop, DO: No financial relationships to disclose

Camilo Zaks, MD, FAAFP: No financial relationships to disclose

Shane Collins, MD, MS: No financial relationships to disclose

Innovations in Polysubstance Overdose Response: More Effective and Compassionate Response

Saturday, April 25, 2026

4:45 PM - 6:00 PM PT

Location: Coronado DE, Level 4

Presenter(s)

[Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM](#)

Addiction Medicine Physician and Addiction Medicine/Harm Reduction Consultant
Kelly S. Ramsey Consulting, LLC
Olivebridge, New York

[Kailin Louise See](#)

Director
Homeless Healthcare Los Angeles
Los Angeles, California

[Mary Brewster, MSW](#)

Harm Reductionist
Ad Astra Harm Reduction
Lawrence, Kansas

Participants attending this presentation will learn via a didactic presentation and interactive case studies about the current unregulated drug supply, with a focus on sedative adulterants, appropriate opioid antagonist use and the concept of compassionate overdose response, appropriate overdose response for the current (and any future) drug supply, and how to augment overdose response with additional tools to better assess and support airway and breathing.

Learning Objectives:

Learners will be able to:

- Upon completion, participant will be able to discuss the current unregulated drug supply, with a focus on sedative adulterants and describe appropriate opioid antagonist use and compassionate OD response.
- Upon completion, participant will be able to describe an appropriate OD assessment and response for the current (and any future) drug supply.

- Upon completion, participant will be able to demonstrate how to augment OD response with tools to better assess and support airway and breathing.

Disclosure(s):

Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM: No financial relationships to disclose

Kailin Louise See: No financial relationships to disclose

Mary Brewster, MSW: No financial relationships to disclose

Let's Practice: Vaping Cessation Strategies for Youth

Saturday, April 25, 2026

4:45 PM - 6:00 PM PT

Location: Harbor A-C, Level 2

Presenter(s)

- TT

Trish Tulloch, MD MS FRCPC

Assistant Professor
University of Toronto
Toronto, Ontario

Amit YOSEF Rotem, MD

Assistant Professor
Centre for Addiction and Mental Health (CAMH)
Toronto, Ontario

- NJ

Naima Javaid, MD

Staff Psychiatrist, Child, Youth and Family Service
Centre for Addiction and Mental Health
Toronto, Ontario

Nicotine vaping is a widespread issue among youth worldwide, with many trying to quit this addiction. This case-based simulation workshop will offer an opportunity to outline evidence-informed vaping

cessation strategies for youth and discuss a developmentally appropriate approach to providing guidance for diverse youth (and from youth) with varying levels of complexity.

Learning Objectives:

Learners will be able to:

- Learning Objectives 1. At the end of this workshop, participants will be able to describe evidence-informed/based vaping cessation approaches for youth.
- 2. At the end of this workshop, participants can outline a developmentally informed approach to introducing guidance for youth (and from youth).
- 3. By the end of this workshop, participants will be able to implement evidence-based approaches for vaping cessation tailored to the unique needs of diverse youth, addressing a range of complexities in each case.

Disclosure(s):

Trish Tulloch, MD MS FRCPC: No financial relationships to disclose

Amit YOSEF Rotem, MD: No financial relationships to disclose

Naima Javaid, MD: No financial relationships to disclose

Medication Call Backs in MOUD: Balancing Diversion Control and Patient-Centered Care

Saturday, April 25, 2026

4:45 PM - 6:00 PM PT

Location: Regatta, Level 4

Presenter(s)

[Robert C. Sherrick, MD, DFASAM](#)

Chief Science Officer
Community Medical Services
Kalispell, Montana

[Hillary Tamar, MD, FASAM](#)

Territory Medical Director
Community Medical Services
Bend, Oregon

Aaron Ferguson, BSW

Harm Reduction Coordinator - Leadership Team-Methadone Liaison
National Survivors Union - Community Medical Services
Austin, Texas

Diversion of MOUD medications remains a major regulatory, clinical, and public health concern. This session will examine the scope of diversion, its real-world consequences, and strategies to prevent it without undermining access to care. A key focus will be the role of medication call backs (MCBs)—their effectiveness, limitations, and impact on patients. Drawing on clinical data, literature, and patient perspectives, presenters will outline evidence-informed approaches to diversion control that balance accountability, equity, and treatment retention.

Learning Objectives:

Learners will be able to:

- Describe the scope and consequences of medication diversion in MOUD programs, including its clinical, regulatory, and public health implications.
- Evaluate the role of medication call backs (MCBs) as a diversion control strategy, including their effectiveness, limitations, and impact on patient engagement and retention.
- Identify evidence-informed approaches to diversion prevention that balance accountability with equitable, patient-centered access to treatment.

Disclosure(s):

Robert C. Sherrick, MD, DFASAM: No financial relationships to disclose

Hillary Tamar, MD, FASAM: No financial relationships to disclose

Aaron Ferguson, BSW: No financial relationships to disclose

Phenobarbital Protocols on Trial: A Point–Counterpoint Debate

Saturday, April 25, 2026

4:45 PM - 6:00 PM PT

Location: Seaport Ballroom, Level 2

Presenter(s)

Robert Cole Pueringer, MD

Addiction Medicine, Medical Toxicology; Medical Director of Substance Use and Addiction Care Program
Essentia Health
Duluth, Minnesota

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM

Director of Addiction Medicine
University of Rochester Medical Center
University of Rochester School of Medicine & Dentistry
Rochester, New York

JoAn Laes, MD

Addiction Physician
Allina
Minneapolis, Minnesota

Evan S. Schwarz, MD, FASAM

Clinical Professor of Emergency Medicine, Medical Toxicology Fellowship Director
UCLA
Los Angeles, California

Non-presenting author(s)

Lewis S. Nelson, MD, MBA

Professor of Emergency Medicine and Medical Toxicology
Florida Atlantic University College Of Medicine
Delray Beach, Florida

Jeremiah D. Fairbanks, DO

Physician
Allina
Inver Grove Heights, Minnesota

- KK

Katie Krieger, MD

Emergency Medicine physician, Addiction Medicine fellow
University of Minnesota
Minneapolis, Minnesota

Phenobarbital has re-emerged as a popular choice for management of alcohol withdrawal syndrome, yet practice remains divided between phenobarbital-first, benzodiazepine-first, and combination regimens. This Focus Session features an expert debate exploring the evidence, safety, and systems-level implications of each approach. Faculty in addiction medicine and medical toxicology will present opposing perspectives and rebuttals, guiding participants through current data, pharmacologic principles, and clinical outcomes to help clarify how best to integrate phenobarbital protocols across acute care and outpatient settings.

Learning Objectives:

Learners will be able to:

- Compare the pharmacologic principles, efficacy data, and safety considerations of phenobarbital, benzodiazepine, and non-benzodiazepine-based protocols for alcohol withdrawal syndrome.
- Evaluate clinical scenarios and patient factors that inform selection of monotherapy, combination, or hybrid “benzodiazepine-sparing” strategies.
- Apply evidence-informed principles to develop or refine alcohol withdrawal syndrome management protocols suited to their institutional resources and patient populations.

Disclosure(s):

Robert Cole Pueringer, MD: No financial relationships to disclose

JoAn Laes, MD: No financial relationships to disclose

Evan S. Schwarz, MD, FASAM: No financial relationships to disclose

Lewis S. Nelson, MD, MBA: No financial relationships to disclose

Jeremiah D. Fairbanks, DO: No financial relationships to disclose

The Healthcare Professional’s Core Resource on Alcohol: Improving Alcohol-Related Care

Developed in Collaboration with the National Institute on Alcohol Abuse and Alcoholism

Saturday, April 25, 2026

4:45 PM - 6:00 PM PT

Location: Gaslamp, Level 2

Presenter(s)

[Laura E. Kwako, PhD](#)

Chief, Treatment, Health Services, & Recovery Branch
NIAAA
Bethesda, Maryland

- GK

George F. Koob, PhD

Director
NIAAA
Bethesda, Maryland

This session will provide an overview of NIAAA's Healthcare Professional's Core Resource on Alcohol with specific focus on several topics within addiction medicine, including fetal alcohol spectrum disorders, integrated care for alcohol-associated liver disease, and alcohol-focused content that is a high priority for inclusion within medical school curricula. Using case examples, we will highlight the importance of the HPCR for the practice of addiction medicine and how it may be used by clinicians across disciplines.

Learning Objectives:

Learners will be able to:

- Upon completion, participant will be able to identify four topics included within the Healthcare Professional's Core Resource on Alcohol.
- Upon completion, participant will be able to describe features of successful integrated care for alcohol-associated liver disease.
- Upon completion, participant will be able to identify alcohol-related content relevant for medical school curricula.

Disclosure(s):

Laura E. Kwako, PhD: No financial relationships to disclose

George F. Koob, PhD: No financial relationships to disclose

Injectable Medications for Addiction: Hands-On Practice for Providers

Room Capacity Limited to 175

Saturday, April 25, 2026

4:45 PM - 6:00 PM PT

Location: Coronado A-C, Level 4

Presenter(s)

Megan Ehret, PharmD, MS, BCPP, FAAPP

Professor, Co-Director Mental Health Program, Vice-Chair of Academic Affairs
University of Maryland, School of Pharmacy
Monrovia, Maryland

Hannah Wilkoff, PharmD, BCPP

Advanced Practice Pharmacist- Psychiatry
University of Maryland School of Pharmacy
Columbia, Maryland

Vincent S. Cavaliere, PharmD, MM, BCPP

Clinical Assistant Director of Pharmacy
Spring Grove Hospital Center - University of Maryland School of Pharmacy
Catonsville, Maryland

Jacob E. McGregor, PharmD

PGY-2 Psychiatry Pharmacy Resident
University of Maryland School of Pharmacy
Nottingham, Maryland

Rebekah Torchon, PharmD, MS

Advanced Practice Pharmacist
University of Maryland Eastern Shore
Princess Anne, Maryland

Adrian Quezada Gonzalez, PharmD

PGY2 Health System Pharmacy Administration and Leadership Resident
University of Maryland Medical Center
Baltimore, Maryland

Every patient requires individualized care, supported by access to all treatment options, including LAI medications—an effective yet often underused intervention. This training includes a 10–15 minute overview of injectable medication fundamentals, followed by a 60-minute small-group, hands-on practice. Participants will rotate through stations with anatomical models, injection supplies, and expert facilitators, receiving step-by-step guidance, anatomical landmark identification, and real-time feedback on intramuscular and subcutaneous techniques. Attendance is limited to 150 participants.

Acknowledgement:

The session titled “Injectable Medications for Addiction: Hands-On Practice for Providers” is partially supported by an unrestricted medical education grant from Alkermes, an unrestricted medical education grant from Braeburn Inc, and unrestricted educational commercial support from Indivior.

No input or influence from these companies was included in the development of the educational content. As an ACCME Provider, ASAM follows the ACCME Standards for Integrity and Independence for Accredited Continuing Education stating that owners and employees of ineligible companies are excluded from participating as planners or faculty, and must not be allowed to influence or control any aspect of the planning, delivery, or evaluation of accredited continuing education.

Disclosure(s):

Megan Ehret, PharmD, MS, BCPP, FAAPP: No financial relationships to disclose

Hannah Wilkoff, PharmD, BCPP: No financial relationships to disclose

Vincent S. Cavaliere, PharmD, MM, BCPP: No financial relationships to disclose

Jacob E. McGregor, PharmD: No financial relationships to disclose

Rebekah Torchon, PharmD, MS: No financial relationships to disclose

Adrian Quezada Gonzalez, PharmD: No financial relationships to disclose

Addressing Substance Use Disorders in Transplant Candidates and Recipients

Sunday, April 26, 2026

8:30 AM - 9:45 AM PT

Location: Gaslamp, Level 2

Presenter(s)

[Thomas Bottyan, MD](#)

Addiction Psychiatrist
VA Northern California
Mather, California

- DA

Divya Ayyala-somayajula, MD MAS

Assistant Professor of Medicine
Thomas Jefferson University
PHILADELPHIA, Pennsylvania

- ST

Steven Tate, MD, MSc, FASAM, FACP

Clinical Assistant Professor
Stanford University School of Medicine
San Francisco, California

Gargi Bhattacharya, MD

Fellow, Addiction Medicine
Stanford University School of Medicine
Stanford, California

Non-presenting author(s)

Deirdra Kelly, MD

Psychiatry Resident
University of California Davis
Sacramento, California

This advanced, case-based workshop explores the evaluation and management of substance use disorders in transplant candidates and recipients, with a focus on real-world clinical challenges. Through multidisciplinary discussion, participants will consider approaches to alcohol, opioid, tobacco, and cannabis use in the peri- and post-transplant settings. Patient perspectives will be included to highlight lived experiences and inform care approaches.

Learning Objectives:

Learners will be able to:

- Identify appropriate approaches to evaluating and treating substance use disorders in patients before and after solid organ transplantation.

- Apply multidisciplinary approaches to address complex clinical scenarios involving substance use in transplant patients, integrating perspectives from hepatology, addiction medicine, and patient experiences.
- Develop strategies for screening, counseling, and medication management to support recovery and long-term transplant outcomes in patients with current or past substance use.

Disclosure(s):

Thomas Bottyan, MD: No financial relationships to disclose

Divya Ayyala-somayajula, MD MAS: No financial relationships to disclose

Steven Tate, MD, MSc, FASAM, FACP: No financial relationships to disclose

Benzodiazepine Tales from the Office - Defining Success and Sharing Stories

Sunday, April 26, 2026

8:30 AM - 9:45 AM PT

Location: Harbor A-C, Level 2

Presenter(s)

[Anthony J. Accurso, MD, FASAM, AAHIVS](#)

Medical Director of Addiction Medicine
Bergen New Bridge Medical Center
Paramus, New Jersey

[Sonya Del Tredici, MD](#)

Academic Internist and Lead Physician for Addiction Services
WellSpan Health
Gettysburg, Pennsylvania

A year after the release of the ASAM Joint Clinical Practice Guideline on Benzodiazepine Tapering, clinicians on the front lines are having to learn and adapt. This interactive session will quickly cover the essentials of benzodiazepine prescribing and then move on to interactive small group case discussions from actual cases. Attendees will grapple with predictions of outcomes before actual outcome of each tale will be revealed. A final discussion topic will be defining the word “success” in regard to tapering.

Learning Objectives:

Learners will be able to:

- Upon completion, participants will be able to: apply the ASAM practice guidelines to specific cases, including calculation of dose benzodiazepine dose equivalents and proper interpretation of urine drug testing.
- Upon completion, participants will be able to: Utilize strategies to empower and motivate patients toward a shared goal of tapering.
- Upon completion, participants will be able to: think critically about the meaning of the word “success” within the context of benzodiazepine prescribing, balancing the concept of taper vs. retention in treatment vs. life functioning.

Disclosure(s):

Anthony J. Accurso, MD, FASAM, AAHIVS: No financial relationships to disclose

Sonya Del Tredici, MD: No financial relationships to disclose

Beyond Kratom: Novel Products Containing 7-OH, Pseudo, MGM, and Kava

Sunday, April 26, 2026

8:30 AM - 9:45 AM PT

Location: Harbor D-F, Level 2

Presenter(s)

- KH

Katherine Hill, MPH

PhD Candidate
Yale School of Public Health
Hamden, Connecticut

Kirsten E. Smith, PhD, LMSW

Consultant
Dial Square LLC
Baltimore, Maryland

Edward W. Boyer, MD PhD

Professor with Tenure
The Ohio State University
Bexley, Ohio

“Gas station heroin?” and “legal morphine?” Think again! In this session we myth-bust and dismantle the pejorative language used to describe kratom-derived products consumed by millions of adults. This session synthesizes epidemiological findings, real-world case reports, preclinical literature, and emerging data to inform attendees about kratom-derived products relevant to their practice. These include products containing 7-hydroxymitragynine (“7-OH”), mitragynine pseudoindoxyl (“pseudo”), kratom-kava products, and emerging MGM analogues. Recommendations are given for how substance use disorder assessment, diagnosis, and treatment can improve.

Learning Objectives:

Learners will be able to:

- Upon completion, participants will be able to describe the basic pharmacology, toxicology, effects, risks, and benefits associated with kratom and kratom-derived products.
- Upon completion, participants will be able to conduct highly specified clinical assessments, as well as better diagnosis and manage SUDs related to kratom-derived products in a data-informed and patient-centered manner.
- Upon completion, participants will be able to define the dynamic state and federal policy and regulatory landscape surrounding kratom and kratom-derived products.

Disclosure(s):

Katherine Hill, MPH: No disclosure to display

Kirsten E. Smith, PhD, LMSW: No disclosure to display

Edward W. Boyer, MD PhD: No financial relationships to disclose

Blueprints for an Inpatient Addiction Consult Service at Pediatric Institutions

Sunday, April 26, 2026

8:30 AM - 9:45 AM PT

Location: Balboa, Level 2

Presenter(s)

[Sukhmeet Sandhu, MD](#)

Addiction Medicine Physician
Children's Hospital Colorado / University of Colorado School of Medicine
Denver, Colorado

Deepa R. Camenga, MD, MHS, FAAP

Associate Professor
Yale School of Medicine
New Haven, Connecticut

Margot Zarin-Pass, MD

Physician
Children's Minnesota
Minneapolis, Minnesota

Abby Montague, MD

Medical Toxicologist and Addiction Medicine Physician
Children's Minnesota
Minneapolis, Minnesota

Learn how pediatric institutions are developing inpatient addiction services from the ground up! This session offers a practical framework for developing pediatric hospital-based addiction services, with real-world lessons on implementation, culture change, and strategies to address developmental, legal, operational, and confidentiality complexities.

Learning Objectives:

Learners will be able to:

- Describe the core components and framework for a hospital-based pediatric addiction consultative service
- Identify key barriers and stakeholders when developing hospital-based pediatric addiction services and analyze strategies to address potential challenges
- Examine current practices in current pediatric addiction consult services and explore opportunities for future development of hospital-based services

Disclosure(s):

Sukhmeet Sandhu, MD: No financial relationships to disclose

Deepa R. Camenga, MD, MHS, FAAP: No disclosure to display

Margot Zarin-Pass, MD: No financial relationships to disclose

Abby Montague, MD: No financial relationships to disclose

Building Community Advisory Boards to Strengthen Patient Voice in Addiction Treatment

Sunday, April 26, 2026

8:30 AM - 9:45 AM PT

Location: America's Cup, Level 4

Presenter(s)

[Elizabeth M. Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM](#)

Professor of Family Medicine and Community Health
University of Wisconsin, Madison School of Medicine and Public Health
Madison, Wisconsin

[Renee M. Cloutier, PhD](#)

Assistant Professor
HEALing Measures Center; Center for Research on Health Care
Pittsburgh, Pennsylvania

[Michael Incze, MD, MEd](#)

Associate Professor
University of Utah
Salt Lake City, Utah

[Evan Done](#)

Advocacy & Public Policy Director
Utah Support Advocates for Recovery Awareness
Salt Lake City, Utah

This workshop examines how Community Advisory Boards can operationalize patient-centered care in addiction treatment. Through discussion and shared experience, participants will identify practical approaches to recruitment, engagement, and ethical collaboration with people engaging in treatment services.

Learning Objectives:

Learners will be able to:

- Describe the role and benefits of Community Advisory Boards (CABs) in advancing patient-centered, equitable, and effective addiction treatment.
- Identify key steps and ethical considerations in developing, implementing, and sustaining CABs within addiction treatment settings.
- Apply strategies for engaging patients and community members as partners in program design and quality improvement efforts.

Disclosure(s):

Elizabeth M. Salisbury-Afshar, MD, MPH, FAAFP, DFASAM, FACPM: No financial relationships to disclose

Renee M. Cloutier, PhD: No financial relationships to disclose

Michael Incze, MD, MEd: No financial relationships to disclose

Evan Done: No financial relationships to disclose

Innovative Strategies for Medication Initiation in Opioid Use Disorder

Sunday, April 26, 2026

8:30 AM - 9:45 AM PT

Location: Harbor G-I, Level 2

Presenter(s)

[Pouya Azar, MD, FRCPC, DABAM](#)

Addiction Psychiatrist, Pain Physician, and Assistant Professor
Vancouver General Hospital & The University of British Columbia
Vancouver, British Columbia

- AH

[Andrew A. Herring, MD](#)

Chief of Addiction Medicine
Alameda Health System
Oakland, California

- MW

Melissa B. Weimer, DO, MCR, DFASAM

Physician/Associate Professor of Medicine (General Medicine) and of Epidemiology (Chronic Diseases)
Yale School of Medicine
New Haven, Connecticut

Laura G. Kehoe, MD, MPH

Assistant Professor of Medicine
Harvard Medical School, MGH Bridge Clinic, Baymark/HCRC OTP
Boston, Massachusetts

For the past three years, Drs. Herring, Weimer, Kehoe, and Azar have delivered a highly rated and interactive session on buprenorphine initiation. This year's workshop builds on that foundation, focusing on cutting-edge strategies for initiating buprenorphine, methadone, and naltrexone across a variety of clinical scenarios in outpatient, hospital, and emergency care settings.

Learning Objectives:

Learners will be able to:

- Describe the unique pharmacology of high-potency synthetic opioids and their implications for initiating medications for opioid use disorder.
- Summarize the current evidence base supporting novel buprenorphine, methadone, and naltrexone initiation strategies.
- Discuss the pharmacologic rationale, clinical applications, and relative risks and benefits of each initiation approach.

Disclosure(s):

Pouya Azar, MD, FRCPC, DABAM: No disclosure to display

Melissa B. Weimer, DO, MCR, DFASAM: No financial relationships to disclose

Laura Gaeta Kehoe, MD, MPH: No disclosure to display

Behavior Change Tools for Prescribers Treating Alcohol Use Disorder

Developed in Collaboration with the Providers Clinical Support System - Medications for Alcohol Use Disorder

Sunday, April 26, 2026

10:15 AM - 11:30 AM PT

Location: Harbor G-I, Level 2

Presenter(s)

- CM

Carla B. Marienfeld, MD, DFAPA, DFASAM

Clinical Professor
University of California San Diego
San Diego, California

John O'Neil, LCSW, LADC

Social Worker
Yale Addiction Medicine Consult Service
Milford, Connecticut

Eve N. Lasswell, PsyD

Psychologist
University of California San Diego
University of California - San Diego
San Diego, California

This interactive workshop introduces prescribers to practical, evidence-based strategies that help patients initiate and stay engaged in alcohol use disorder treatment. Through skill demonstrations and role-play using real patient cases, participants will explore tools like Behavior Chain Analysis, the RAC Framework, safety planning, and urge surfing. These simple, actionable templates are designed for prescribers without behavioral health specialization who want effective ways to support recovery and improve treatment outcomes.

Learning Objectives:

Learners will be able to:

- Understand how prescribers can effectively integrate behavior change strategies with pharmacologic treatment for patients with AUD to enhance engagement, support sustained recovery, and improve retention in care.
- Utilize Behavior Chain Analysis, RAC Framework, safety and relapse prevention planning, and urge surfing to develop personalized strategies that support behavior change and treatment adherence in patients with AUD.
- Demonstrate how to utilize behavior change strategies in the treatment of patients with AUD, including adapting approaches for a variety of care settings.

Disclosure(s):

Carla B. Marienfeld, MD, DFAPA, DFASAM: No disclosure to display

John O'Neil, LCSW, LADC: No financial relationships to disclose

Eve N. Lasswell, PsyD: No financial relationships to disclose

Cracking the Code: Building a Statewide Perinatal SUD Network

Sunday, April 26, 2026

10:15 AM - 11:30 AM PT

Location: Harbor A-C, Level 2

Presenter(s)

Melinda Ramage, FNP-BC, CARN-AP, LCAS

Director, Perinatal Substance Use Disorder Network
Governor's Institute
Asheville, North Carolina

Hendree E. Jones, PhD, LP

Professor
University of North Carolina at Chapel Hill
Carrboro, North Carolina

Olivia A. Caron, PharmD, BCACP, CPP

Clinical Pharmacist Practitioner
MAHEC
Asheville, North Carolina

Non-presenting author(s)

Mateo Eckstat, MD, MPH

Director REACH Program
REACH Program, Cone Health
Greensboro, North Carolina

Nicole F. Ross, LCAS, CCS, NCPSS

Regional Director
BHG Recovery
Waynesville, North Carolina

- EJ

Elisabeth Johnson, PhD, FNP-BC, CARN-AP, LCAS

Director of UNC Horizons
UNC Chapel Hill
Carrboro, North Carolina

Michael Baca-Atlas, MD, FASAM

Clinical Associate Professor
UNC
Raleigh, North Carolina

David Hallmark Ryan, MD, FASAM, FACOG

Division Chief of Addiction Medicine
ECU Health
Winterville, North Carolina

This workshop is an interactive session that challenges participants to examine the real-world barriers in PSUD care in their own community and leave with strategies to build systems change. Participants will participate as small groups to learn more about the North Carolina PSUD Network and use the evolution of the NC PSUD Network as their blueprint to identify strategies to improve PSUD access and collaboration in their own state.

Learning Objectives:

Learners will be able to:

- Explain the fragmented systems of perinatal substance use disorder care and the impact this fragmentation has on perinatal substance use disorder morbidity and mortality.
- Identify key components of statewide PSUD care collaboration as presented from the NC PSUD Network. Identify strengths and opportunities in their home communities to build a similar collaborative structure.

- Analyze principles of co-design for network build and sustainability across patients, community, and key stakeholders with a tool to use and facilitate easier implementation to be ready to use at conference end.

Disclosure(s):

Melinda Ramage, FNP-BC, CARN-AP, LCAS: No financial relationships to disclose

Hendree E. Jones, PhD, LP: No financial relationships to disclose

Olivia A. Caron, PharmD, BCACP, CPP: No financial relationships to disclose

Mateo Eckstat, MD, MPH: No financial relationships to disclose

Nicole F. Ross, LCAS, CCS, NCPSS: No financial relationships to disclose

Elisabeth Johnson, PhD, FNP-BC, CARN-AP, LCAS: No financial relationships to disclose

Michael Baca-Atlas, MD, FASAM: No financial relationships to disclose

David Hallmark Ryan, MD, FASAM, FACOG: No financial relationships to disclose

Expanding Access: Low-Barrier, Hepatitis C Treatment in Addiction Clinics

Sunday, April 26, 2026

10:15 AM - 11:30 AM PT

Location: America's Cup, Level 4

Presenter(s)

- MT

Marissa Tan, DO, MPH, MAS

Attending physician
Cooper
Camden, New Jersey

- XG

Xin Gao, PharmD, MSc

Clinical Pharmacist
Cooper University Healthcare
Camden, New Jersey

Rachel Ehrman-Dupre, MD

Attending Physician
Cooper University Healthcare
Philadelphia, Pennsylvania

This workshop is ideal for addiction medicine providers, clinic managers, and care team members interested in reducing barriers to HCV care and improving health equity. No prior HCV treatment experience is required. This session will harness participants' varied experiences to facilitate a robust brainstorming session; Participants will walk away with actionable next steps tailored to their clinical setting, regardless of whether it's in the early stages of HCV screening or advanced stages of developing innovative new treatment delivery models.

Learning Objectives:

Learners will be able to:

- Learn to screen, diagnose, treat, and monitor hepatitis C treatment within office-based addiction clinics.
- Learn how to use a hepatitis C cascade of care to identify system barriers to treatment.
- Learn how to navigate regulatory, systemic, and psychosocial barriers to care.

Disclosure(s):

Marissa Tan, DO, MPH, MAS: No financial relationships to disclose

Xin Gao, PharmD, MSc: No financial relationships to disclose

Rachel Ehrman-Dupre, MD: No financial relationships to disclose

Gas Station Highs

Sunday, April 26, 2026

10:15 AM - 11:30 AM PT

Location: Harbor D-F, Level 2

Presenter(s)

Alaina R. Steck, MD, FACMT, FASAM

Associate Professor of Emergency Medicine
Emory University
Atlanta, Georgia

Steven Quam, MD

Addiction Medicine Fellow
University of Minnesota
Saint Paul, Minnesota

JoAn Laes, MD

Addiction Physician
Allina
Minneapolis, Minnesota

Jeremiah D. Fairbanks, DO

Physician
Allina
Inver Grove Heights, Minnesota

Non-presenting author(s)

Robert Cole Pueringer, MD

Addiction Medicine, Medical Toxicology; Medical Director of Substance Use and Addiction Care Program
Essentia Health
Duluth, Minnesota

Evan S. Schwarz, MD, FASAM

Clinical Professor of Emergency Medicine, Medical Toxicology Fellowship Director
UCLA
Los Angeles, California

Lewis S. Nelson, MD, MBA

Professor of Emergency Medicine and Medical Toxicology
Florida Atlantic University College Of Medicine
Delray Beach, Florida

“Gas station” and internet drugs such as tianeptine, phenibut, kratom, and alkyl nitrites exist in a lax regulatory environment that permits easy access, leading to increased emergency presentations for intoxication, withdrawal, and unique harms. In this session, toxicology, emergency medicine, and addiction experts use case vignettes to teach rapid toxidrome recognition, practical management, and effective discharge counseling grounded in current FDA and CDC alerts and recalls. Attendees will gain practical tools, algorithms, and up-to-date references for bedside management.

Learning Objectives:

Learners will be able to:

- Identify common “gas station” or internet-accessible agents (e.g., tianeptine, alkyl nitrites/“poppers,” phenibut, kratom) and describe core pharmacology and toxidromes.
- Recognize intoxication, withdrawal, and unique complications including poppers maculopathy, severe tianeptine toxicity, phenibut withdrawal, and kratom-associated adverse events.
- Apply evidence-informed outpatient and acute care strategies, including supportive care, targeted antidotes and adjuncts, and discharge harm-reduction counseling specific to unregulated products.

Disclosure(s):

Alaina R. Steck, MD, FACMT, FASAM: No financial relationships to disclose

Steven Quam, MD: No financial relationships to disclose

JoAn Laes, MD: No financial relationships to disclose

Jeremiah D. Fairbanks, DO: No financial relationships to disclose

Robert Cole Pueringer, MD: No financial relationships to disclose

Evan S. Schwarz, MD, FASAM: No financial relationships to disclose

Lewis S. Nelson, MD, MBA: No financial relationships to disclose

LAI Buprenorphine in Criminal Justice Settings: Strategies and Tools for Implementation

Sunday, April 26, 2026

10:15 AM - 11:30 AM PT

Location: Gaslamp, Level 2

Presenter(s)

- ER

[**Eowyn Rieke, MD MPH**](#)

Addiction Medicine Physician
Multnomah County Department of Health/Corrections Health
Portland, Oregon

Stephen Kane, MD MPH

Medical Director- Corrections Health
Multnomah County Health Department
Portland, Maryland

Kendra Birnley, RN, MA, MEd, PhDc

Lead RN for Transition Services Program
Multnomah County Health Dept, Corrections Health
Portland, Oregon

Non-presenting author(s)

- EO

Ederlinda Ortiz, CHW

Manager
Multnomah County Health Dept/Corrections Health
Portland , Oregon

- DG

David Green

Administrator
Multnomah County Transition Services Program
Portland, Oregon

- CK

Courtney M. Kenney

Senior Harm Reduction Specialist
Multnomah County Health Department
Portland, Oregon

Long-Acting Injectable Buprenorphine is one of the best evidence-based treatments for OUD, with improved outcomes from retention in care to overdose deaths. Justice-involved people have high rates of OUD and overdose, and some of the greatest barriers to engagement in care. Why can't we bring these 2 together? In this presentation we will review the implementation of a LAIB Program in an urban jail, as well as key tips gleaned from interviews of carceral health leaders across the country.

Learning Objectives:

Learners will be able to:

- - Articulate the evidence on outcomes associated with Long-Acting Injectable Buprenorphine (LAIB)
- - Describe key challenges to implementing a LAIB program in a criminal-justice setting
- - Discuss strategies to overcome challenges to LAIB program development

Disclosure(s):

Eowyn Rieke, MD MPH: No financial relationships to disclose

Stephen Kane, MD MPH: No financial relationships to disclose

Kendra Birnley, RN, MA, MEd, PhDc: No financial relationships to disclose

Ederlinda Ortiz, CHW: No financial relationships to disclose

David Green: No financial relationships to disclose

Courtney M. Kenney: No financial relationships to disclose

Retention Beyond Benchmarks: Patient-Centered Tele-MOUD Care in the Fentanyl Era

Sunday, April 26, 2026

10:15 AM - 11:30 AM PT

Location: Balboa, Level 2

Presenter(s)

[Laura Monico, PhD](#)

Director of Research and Innovation
Boulder Care
Avondale, Pennsylvania

Ayesha Appa, MD

SVP, Head of Medical Affairs & Assistant Professor of Medicine
Boulder Care & UCSF
Mill Valley, California

Danielle Bellosi, NCPRSS, CPRC

Peer Supervisor
Boulder Care
Boise, Idaho

Elizabeth Bambury, MPH

Research Project Manager
Boulder Care
Andover, Massachusetts

Non-presenting author(s)

Jennifer K. Foreman, DNP, AGNP-C, WHNP-BC

Nurse Practitioner
Boulder Care
Portland, Oregon

Melody Avila, DNP

Nurse Practitioner
Boulder Care
Portland, Oregon

Stephen A. Martin, MD, EdM

Medical Director for Research, Education, and Quality
Boulder Care
Northfield, Massachusetts

This session presents groundbreaking results from more than 20,000 patients in a telehealth-only program, showing that high buprenorphine retention is not only possible but sustainable—with outcomes far exceeding national benchmarks. Presenters will unpack the care model behind these results, weaving together real-world data and patient voices to illuminate what keeps people engaged in treatment in the fentanyl era.

Learning Objectives:

Learners will be able to:

- Compare retention outcomes in a large telehealth-only MOUD program to historical benchmarks, with attention to differences by buprenorphine transition pathway.
- Identify program strategies (i.e. harm reduction, peer integration, tailored cadence, and non-punitive re-engagement) that support sustained retention in the fentanyl era.
- Identify patient barriers to buprenorphine engagement and translate community insights into practical strategies to improve equity and continuity of care.

Disclosure(s):

Laura Monico, PhD: No financial relationships to disclose

Ayesha Appa, MD: No disclosure to display

Danielle Bellosi, NCPRSS, CPRC: No financial relationships to disclose

Jennifer K. Foreman, DNP, AGNP-C, WHNP-BC: No financial relationships to disclose

Melody Avila, DNP: No financial relationships to disclose

Elizabeth Bambury, MPH: No financial relationships to disclose

Stephen A. Martin, MD, EdM: No financial relationships to disclose